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Osteoporosis is a major public health problem in men and women.  Low bone mineral density 
(BMD) is a major risk factor for fracture.  Fractures have major implications for morbidity and 
mortality.   
This research project evaluated correlates of trabecular and cortical vBMD at the radius 
and tibia in primarily Caucasian men aged 69 years or older using the Osteoporotic Fractures in 
Men study (MrOS). The correlation between serum 25-hydroxy vitamin D [25(OH)D] and bone 
density, content, geometry and strength was also assessed using Caucasian men from MrOS and 
men of African descent from the Tobago Bone Health Study, aged 65 years and older.  We also 
investigated the longitudinal impact of serum leptin and adiponectin on bone loss and fractures in 
the Health Aging and Body Composition study (Health ABC) in men and women, aged 70 years 
and older, of African American and Caucasian descent.  
Our findings have important public health implications. We have a better understanding 
of how different factors are correlated with trabecular and cortical and vBMD.  Future research 
can generate hypotheses to evaluate these associations prospectively.  Men of African descent 
had significantly higher 25(OH)D than Caucasians, which has never been reported.  Serum 
25(OH)D was positively correlated with indices of bone strength in Caucasian men, but not men 
of African descent.  Serum 25(OH)D thresholds were identified at an estimated 20 ng/ml (lower 
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than previous consensus of 30 ng/ml), greater levels of 25(OH)D had minimal effects on bone 
measures. Significant correlations between 25(OH)D occurred only at cortical regions.  
Prospective studies that evaluate the impact of 25(OH)D on trabecular and cortical vBMD loss 
are needed.  There was an association between higher adiponectin and greater risk of incident 
fracture in men only.  We also report that adiponectin predicted greater hip areal BMD (aBMD) 
loss among women, but not men.  The impact of leptin on bone loss and incident fractures was 
largely attenuated by BMI and weight change. This study provides strong evidence that higher 
levels of adiponectin may increase the risk of bone loss and fracture.  Studies are needed to 
explain these differential associations for adiponectin in women and men.  
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1.0  DISSERTATION OVERVIEW AND OBJECTIVES 
Osteoporosis is defined as a systemic bone disease characterized by low bone mass and 
mircoarchitectural deterioration of bone tissue, with a subsequent increase in bone fragility and 
susceptibility to fracture.1  The World Health Organization (WHO) defines osteoporosis as 
having a BMD of less than or equal to 2.5 standard deviations (SDs) below the mean BMD of a 
young adult.2  Osteoporosis has major public health implications for aging men and women.  In 
1995, it was estimated that 18% of women, and 6% of men, 50 years of age or older in the 
United States (US) had this disorder.2 An abundance of research has been conducted to better 
understand the etiology and prevention of osteoporosis in women. There is also growing 
recognition that osteoporosis and fractures in older men are significant public health problems 
that contribute to disability and premature death.3  Men over the age of 50 have a 13% estimated 
risk of developing an osteoporotic fracture.4  Mortality rate after a hip fracture has been shown to 
be greater in men than women.1   
In past studies, BMD measurements were primarily made at the lumbar spine and hip by
using dual energy x-ray absorptiometry (DXA).  Two major limitations of the DXA technique is 
that it cannot distinguish cortical and trabecular bone and only provides measurement for the 2 
dimensional areal BMD (aBMD) rather than the 3 dimensional volumetric BMD (vBMD).  
Bones of larger width and height tend to be thicker, and since bone depth is not factored into 
DXA, reliance on aBMD inherently underestimates the bone density.5  Measurement of vBMD is 
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advantageous because it is independent of skeletal size.  A method known as quantitative 
computed tomography (QCT) has been developed to assess vBMD, distinguish between cortical 
and trabecular bone, and provide information on geometry and bone strength.6  Bone geometry is 
an important determinant of bone strength and fracture risk.7  The two primary locations for QCT 
measurements are at the central (lumbar spine and proximal femur) and peripheral (radius and 
tibia) regions of the skeleton.8 Two recent large studies in Tobago examined correlates of 
trabecular and cortical vBMD in men of African descent.9,10  However, no comprehensive 
studies to date have examined correlates of vBMD in older white men.   
Vitamin D is important for bone growth11 and preservation.12 Higher serum 25-
hydroxyvitamin D levels enhance calcium absorption.13  Calcium is the structural component of 
the bone and low levels in the body can lead to bone resorption that is directed by the parathyroid 
hormone (PTH).14  Vitamin D deficiency can cause secondary hyperparathyroidism, resulting in 
high bone turnover and bone loss.15  Adequate vitamin D levels are needed to maintain PTH 
levels and help prevent major bone loss.16  Most comprehensive studies examining the 
association between serum 25(OH)D and BMD in men have evaluated this in participants of 
Caucasian descent.17-20  Additionally, there is a dearth of studies that determine the association 
between serum 25(OH)D and bone geometry21 and bone strength.   
Leptin is a hormone secreted by adipose cells that have been shown to impact bone 
mineral density (BMD).22  This molecule has been shown to be highly correlated with body fat 
mass23 and been involved in fat metabolism and appetite control.24 Leptin has been shown to 
play a role in the modulation of bone formation by enhancing differentiation of bone marrow 
stroma into osteoblasts and inhibiting its differentiation into osteoclasts and adipocytes.25,26 
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Adiponectin is another adipocyte derived hormone that regulates insulin sensitivity and has anti-
inflammatory properties.27 Unlike leptin, adiponectin levels are lower among individuals with 
obesity.28  Adiponectin and its receptors are produced by human bone-forming cells, suggesting 
that adiponectin may be a hormone linking bone and fat metabolism29.  Adiponectin may have 
harmful effects on bone by stimulating the receptor activator of nuclear factor-κB ligand 
(RANKL) pathway and inhibiting the production of the decoy receptor for RANKL, 
osteoprotegerin.30  However, adiponectin administration has also been shown to increase 
osteoblast proliferation and differentiation, alkaline phosphatase activity (ALP), a marker of 
bone formation, and mineralization.31  Few studies have examined the impact of these hormones 
on  incident fractures32,33 and changes in aBMD34,35 and vBMD.    
 This dissertation aims to identify factors associated with fracture, bone mineral density, 
bone geometry, and bone strength in older adults.  A cross-sectional analysis in a sample of 
primarily Caucasian men will examine correlates of trabecular and cortical vBMD of the radius 
and tibia and see if they differ.  Another study, will test the hypothesis that higher levels of 
serum 25(OH)D will be positively associated with vBMD, bone geometry, and bone strength 
measures in men of Caucasian and African Heritage.  Finally, a prospective study will examine 
the impact of baseline serum leptin and adiponectin on the risk of a fracture, hip aBMD and 
spinal vBMD loss, in men and women of Caucasian and African American descent.   
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2.0  INTRODUCTION 
2.1 EPIDEMIOLOGY OF OSTEOPOROSIS AND OSTEOPOROTIC 
FRACTURES  
2.1.1 Prevalence of osteoporosis and osteoporotic fractures 
Approximately 22 million women and 12 million men in the US are considered to have low bone 
mass (osteopenia or osteoporosis).(2)  In the United States, there are approximately 700,000 
vertebral fractures, 300,000 hip fractures, 250,000 wrist fractures, and 300,000 fractures at other 
skeletal sites.(35)  The estimated number of hip fractures worldwide is expected to increase from 
1.66 million in 1990 to 6.26 million in 2050.(36)  Currently, North America and Europe account 
for approximately half the hip fracture in the world, however by 2050 this estimate is expected to 
be reduced to 25% because of the large growth of fractures in Asia.(36)  The mortality rate 1 
year after having a hip fracture is estimated to be around 20%.(37)   Among white women with 
osteoporosis, 40 to 50% are expected to have a hip fracture.(38;39)  The highest incidence rates 
for hip fracture in men were found in Scandinavian countries while some of the lowest have been 
reported among blacks and Asians.(40;41)  Men over the age of 50 have a 13% lifetime 
estimated risk of developing an osteoporotic fracture in the US, although in Sweden it is 
estimated to be 23%.(4)  Men with low BMD have an estimated 50% lower fracture rate than 
women with low BMD.(2)   
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2.1.2 Mortality and Morbidity 
Nearly one-third of hip fractures result in nursing home admissions and one-fifth of patients with 
hip fractures die within the year following their fracture.(42)  The incidence of hip fractures in 
men is uncommon till after the age of 75.(1)  However, mortality rate after a hip fracture is 
greater in men than women.(1)  African Americans who sustain a hip fracture have increased 
morbidity and nearly twice the mortality as Caucasian Americans.(37;43)   
2.1.3 Economic Burden 
Fractures accounted for an estimated $17 billion (25% in men) in health care service usage in 
2005, with costs likely to rise to $25 billion in 2025.(44)  In terms of type of health service for 
osteoporotic fractures, 62.4% of the costs are attributed to inpatient hospitalization costs and 
28.2% to nursing home care.(45)  More than 20% of osteoporotic related costs were due to 
fractures.(44)  Among men, Caucasians have accounted for an estimated 80% of all costs related 
to fractures.(44)  
2.2 PATHOPHYSIOLOGY OF OSTEOPOSOSIS 
As people get older, resorption of the minerals in the cortical layer can lead to an inexorable loss 
of trabecular bone and a widening of the bone cavity.(46)  Also, bones tend to get thicker with 
age however they are not getting any denser as peak bone mass tends to decline.(47)  Bone 
architecture and continual remodeling combine to have a huge impact on the pathophysiology of 
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osteoporosis.  For example, having a wider femur at a young age might put individuals at risk for 
hip fractures late in life because wider bones tend to have thinner cortical layers which are more 
susceptible to resorption later in life.(48)  Cellular pathophysiology is influenced by osteoclasts 
which pump protons into the extracellular space lowering the pH in their own microenvironment 
which results in dissolving of the bone mineral.(49)  Osteoblasts are bone cells that lay down 
new bone material and facilitate mineralization of the bone.  The balance between these activities 
by osteoblasts and osteoclasts results in whether bone is made, maintained or lost.(50)  Any 
increase in remodeling activity tends to result in bone loss because bone formation takes longer 
to occur than resorption.(51)  The balance between bone formation and resorption is primarily 
mediated by the interaction between receptor activator of nuclear factor kB ligand (RANKL) and 
osteoprotegerin (opg). Hormones such as parathyroid hormone (PTH)(52), and 
prostaglandins(53), bind to receptors on osteoblasts.  This initiates the release of RANKL which 
binds to the RANK receptor on osteoclasts leading to the proliferation and differentiation of 
these cells followed by increased bone resorption.(6;54-57) OPG is a cytokine that is also 
released by osteoblasts which can bind to RANKL, preventing RANK and RANKL from coming 
into contact and thus reducing resorption of the bone.(58) 
            The osteoclast arises from hematopoietic stem cells and is a bone lining cell responsible 
for bone resorption. Produced by the stromal cell, macrophage colony stimulating factor (M-
CSF) is responsible for the differentiation of hematopoietic stem cells into pre-oseteoclasts. The 
receptor activator of nuclear factor kappa B (RANK) receptor, and receptor activator of nuclear 
factor kappa B ligand (RANKL) is required for the differentiation of osteoclasts. When RANKL 
activates RANK receptors on the pre-osteoclasts, the cells fuse and differentiate into mature 
multinucleated osteoclasts. The mature osteoclasts solubilize the mineral and organic 
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constituents of bone matrix by synthesizing lysosomal enzymes and activating collagenase. High 
levels of calcium, magnesium, phosphate and products of collagen are released into the 
extracellular fluid as the osteoclasts tunnel into the mineralized bone.(31)  
2.3 AGE-RELATED CHANGES IN TRABECULAR AND CORTICAL BONE  
Past studies have shown that reduction in trabecular vBMD occurs before mid-life (age 20-49) in 
men and women and continues unabated through life.(6;56;57).  In a recent study, (among 
women and men, aged <50 years) trabecular bone loss accounted for 37% and 42% of lifetime 
bone loss, respectively.  In contrast, the amount of cortical bone lost before 50 years of age 
represented only 6% in women and 15% in men.  Mechanisms for early onset of trabecular 
vBMD loss remain largely unknown.  Riggs et al. hypothesized that decreases in paracrine 
production of the hormones IGF-1 and IGF-2 by osteoblasts may contribute to significant 
trabecular bone loss early on in life.(6)  Prior findings show that major cortical bone loss occurs 
late in life (age ≥50).(6;54-57) This observation is likely related to being sex steroid deficient 
late in life.(6)  In women, substantial cortical bone loss has been shown to occur after mid-life 
(age ≥50) in association with menopause and estrogen deficiency.(59) However, cortical bone 
loss in men seems to decrease at a constant rate in young adulthood until accelerating late in life 
(age ≥75).(6)  
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2.4 MEASUREMENT OF BONE STRENGTH  
In past studies, BMD measurements were primarily made at the lumbar spine and hip using dual 
energy x-ray absorptiometry (DXA). A major limitation of the DXA technique is that it cannot 
distinguish cortical and trabecular bone and only provides measurement for the 2 dimensional 
areal BMD (aBMD) rather than the 3 dimensional volumetric BMD (vBMD).  Bones of larger 
width and height tend to be thicker, and since bone depth is not factored into DXA, reliance on 
aBMD inherently underestimates the bone density.(46) Measurement of vBMD is advantageous 
because it is independent of skeletal size.  A method known as quantitative computed 
tomography (QCT) has been developed to assess vBMD, distinguish between cortical and 
trabecular bone, and provide information on geometry or structure.(6) The two primary locations 
for QCT measurements are at the central (lumbar spine and proximal femur) and peripheral 
(radius and tibia) regions of the skeleton.  
Bone geometry is an important determinant of bone strength and fracture risk.(7)  The 
cross-sectional area of the medullary cavity increases in old age as endosteal resorption outpaces 
periosteal apposition, resulting in reduction in the cortical area and bone strength.(60)  Reduction 
in cortical area has been shown to be more pronounced in women than in men.  This is primarily 
due to the fact that men have greater periosteal apposition than women, despite having similar 
rates of endosteal resorption.(61)  Researchers have found that resistance of bone to compressive 
(axial) loads primarily depends on the cortical area (CA), whereas resistance to bending and 
torsion depends on the distribution of cortical mass about the bone center.(62) 
Bone strength is largely influenced by a combination of bone material properties and 
cross-sectional geometry.(7)  There are several ways to measure bone strength using QCT.(63)  
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The bone's polar and axial moments of inertia measure the redistribution of cortical mass by  
combining the distribution and area of cortical bone as an index of bending and torsional 
strength.(64)  The polar moment of inertia (Ipolar, mm4) of a bones cross-sectional area can 
determine the bones ability to resist torsion.(63) It is calculated by taking the ∫ of the cross-
sectional area of a voxel (A) multiplied by the square of the center of gravity distance to the 
cross-sectional area of the voxel (d2), ∫ d2A.(65)  The axial moment of inertia (Iaxial, mm4) is a 
measure of the distribution of cortical bone mass about the center of the cross-section of a tubular 
bone and is related to bending strength of bone.(66)  Section Modulus (SM) is the maximum 
bending stress in a cross-section (mm3).  SM =∫ d2A/dmax, where dmax= the maximum distance of 
any of the voxels from the center of gravity.(65)  As mentioned earlier, bone strength is 
influenced by bone material properties and cross-sectional geometry.  A key bone material 
property is the elastic modulus or stiffness.  It is difficult to measure stiffness in vivo however 
the cortical vBMD is approximately linear to the elastic modulus and can be used as surrogate 
for bone material property.(64)  The polar or axial strength-strain indices (SSIp, SSIx) take bone 
material into account by calculating the weighted bone density.  The strength strain indices 
denote the density-weighted polar or axial section moduli and reflect the torsional and bending 
rigidity of the long bone shaft (mm3).(67) SSI= =∫ d2A*(vBMDvox/vBMDmax)/dmax, where 
vBMDvox=bone density of a voxel and vBMDmax=1200 mg/cm3, maximal bone density.(65)   
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2.5 CORRELATES AND RISK FACTORS FOR LOWER BMD THAT HAVE 
BEEN IDENTIFIED 
2.5.1 Demographic measures 
Demographic risk factors for osteoporosis include older age, female sex, and white race.(35)  
African Americans have been shown to have higher BMD than Caucasians independent of body 
weight.(3;68;69) An association between genetics and BMD has been shown in several 
studies.(38;70-73)  A negative association between parental history of fracture and lower BMD 
was found in two studies on older women.(38;71)  Twin studies have shown that up to 80% of 
the variance for BMD is controlled by genetics.(35)  Candidate genes researched that are known 
to influence bone metabolism include the vitamin D receptor (VDR)(74) the type I collagen 1 
gene(75), the estrogen receptor(76), Apolipoprotein E (ApoE), transforming growth factor Β 1 
(TGFB1) and interleukin-6.(72) VDR is a receptor involved in generation of proteins which are 
involved in calcium absorption in the intestines.  The absence (BB genotype) of BsmI restriction 
site for the VDR receptor in intron 8 is present in 17% of Caucasians and 13% of African 
Americans BsmI.(73)  A study in Australia on women with a mean age of 52.5 years found that 
subjects with the BB genotype had significantly lower lumbar spine and femoral neck aBMD 
than those with the bb genotype.(74) The FokI polymorphism (ATG to ACG) found in 18% of 
Caucasians and 4-6% of African Americans has been shown to be associated with lower spinal 
and femoral neck BMD in three studies.(73;77)  Subjects with the APOE*4 allele product appear 
to have appear to have reduced levels of vitamin K and impaired carboxylation of osteocalcin 
compared to subjects with the APOE*2 or APOE*3 allele products.(73)  Some studies have also 
shown that individuals with this allele have more likely to have lower BMD than others.(78;79)   
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2.5.2 Anthropometric measures 
Greater weight has been shown to be associated with a lower probability of osteoporosis.  
Several hypotheses have been proposed for this observation.  Larger skeletal frames and greater 
muscle and fat compartments in heavy individuals may increase the mechanical load on the 
skeleton promoting mineralization and structural adaptive responses that can strengthen 
bone.(80)  In postmenopausal women, adipose tissue is the principal site for estrogen 
biosythnesis.  Hormones leptin and insulin, have been associated with increased body weight and 
BMD.(81)  On the other hand, heavier weight was related to lower cortical vBMD in some 
studies.(9;82) It is also possible that mechanical factors or differences in bone geometry may 
explain these findings.  Increased mechanical loads can lead to bone microdamage, increased 
bone turnover, and a transient reduction in cortical vBMD.(83) Also, overweight individuals may 
adapt by increasing periosteal bone diameter requiring lower cortical density to maintain the 
same strength.(84)  
Findings examining the relationship between height and BMD have been conflicting.  
Several studies have found an inverse relationship between height and BMD,(3;18;85) while 
others have found a positive association.(86;87) Taller individuals are known to experience 
larger height loss and have been shown to be a higher risk of fracture than others.(38;88;89)   
2.5.3 Lifestyle factors 
Certain lifestyle factors have been found to be associated with BMD.  Most studies have found 
that smokers are at an increased odds of having lower BMD compared to nonsmokers 
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independent of body weight.(55;90;91)  In vitro studies have shown that the toxicity from 
nicotine may decrease osteoblast activity.(92;93)  Smoking may also have a negative effect on 
BMD by decreasing calcium absorption in the intestines.(94)  Smoking also may increase the 
odds of lower BMD by altering estrogen metabolism in women.(95) Very high levels of alcohol 
have been found to increase the risk for osteoporosis,(96;97) while low to moderate intake may 
benefit, or have no effect on BMD.(3;3;86;87;91;91;98-100) It has been hypothesized that 
alcohol may increase BMD by raising sex steroid levels.(98;99) High caffeine intake has been 
implicated as a risk factor for lower BMD in men(87) and women.(38;101-103)  Caffeine may 
reduce BMD by decreasing intestinal calcium absorption, however, it may also be a marker for 
low calcium consumption.(104)  Low physical activity has been identified as a risk factor for 
lower BMD.  Lack of physical activity or immobility may cause bone loss by increasing bone 
resorption.(105-107) Two studies on postmenopausal women found that walking significantly 
reduced bone mineral density.(108;109)  A study on young men from Sweden found a positive 
association between physical activity and greater trabecular volumetric bone mineral density 
vBMD.(110) The effects of calcium intake and vitamin D on BMD are well documented.  In 
regards to calcium, several studies have found a positive association with BMD.(3;87;91;100)  
An adequate intake of calcium is needed to ameliorate the progressive loss of bone with age and 
avoid osteoporosis.(111) Most studies on vitamin D intake has also been found to have a positive 
effect on BMD.(112-116) Low levels of serum vitamin D reduce the rate of calcium absorption 
in the intestines which subsequently can lower BMD.(117) 
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2.5.4 Medical conditions 
Several medical conditions have been consistently related to BMD.  Diabetes mellitus, despite 
being related to higher fracture risk, has been associated with higher BMD, independent of 
weight, in most studies on older men(3;118;119) and women.(120;121)  Factors associated with 
greater BMD in individuals with diabetes compared to non-diabetics include greater abdominal 
obesity,  growth factors(3) and use of statins.(118) Depression has also been linked to lower 
BMD independent of the fact that depression may lead to lower weight.(122;123)  
Hypothyroidism can increase the risk of lower BMD in men(124) and women.(125;126)  Excess 
thyroid hormone in the body has been known to decrease BMD by increasing bone 
resorption.(127)  Diseases that result in cognitive impairment such as stroke and Parkinson’s 
disease have also been shown to be risk factors for reduced BMD in women, though the 
mechanism is not well understood.(38;128;129)  Most studies have a negative association 
between history of a gastrectomy and BMD.(86;130)  The operational removal of the stomach 
had been known to result in loss of weight and reduction in calcium absorption, which 
subsequently decreases BMD.(130;131)  A previous link between OA and higher BMD has been 
established.(3;132;133) Though the mechanism is not well understood it has been hypothesized 
that genetics,(3;133) sex steroid levels(3) and osteophyte(86) formation may increase BMD 
among those with OA.  Two large studies have found a positive association between 
hypertension and BMD in men of Caucasian(3) and African descent.(134)  This  association 
though not completely understood may reflect higher insulin levels(3) or may reflect 
confounding by the use of certain medications such as thiazide (TZ) diuretics that may increase 
vBMD due to their ability to improve calcium retention.(135-138)  Studies have found a negative 
correlation between RA and BMD(86;139;140) in men and women.  The negative association 
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between RA and BMD can be explained by an increase in inflammatory activity among those 
with RA resulting in a greater rate of bone loss than normal.(139)  Inflammatory activity 
influenced by C-reactive protein (CRP) and the erythrocyte sedimentation rate (ESR) has been 
shown to increase bone resorption in individuals with RA.(141)    
2.5.5 Medications 
In addition to TZ diuretics, other medications may also increase or decrease BMD.  
Corticosteroid have been shown to decrease BMD.(142)  Ant-depressive treatment, specifically 
selective serotonin re-uptake inhibitors have been linked to lower BMD in some studies 
independent of depression or weight.(3;143) Studies have hypothesized that SSRI use may 
reduce osteoblast activity by disrupting the serotonin transport gene leading to lower 
BMD.(143;144)  Another study on mice found that those lacking the serotonin transporter gene 
have lower BMD than wild-type mice.(145) Statin use has been found to be associated with 
greater BMD in independent of MI and body weight, in study on postmenopausal women(146) 
and another on older men.(3) Past studies have showed that non-steroidal anti-inflammatory drug 
use was associated with greater BMD which may reflect a role of prostaglandin.(3;147)  
2.5.6 Neuromuscular function 
A positive association between neuromuscular function and BMD has been documented in 
several studies.(3;55;148-152)  Though the rationale for this association is not entirely clear, it is 
thought that this may be due to the increased skeletal loading that occurs as a result of having 
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stronger muscles.(149)  However, a recent study on men of African descent in Tobago found an 
inverse association between grip strength and BMD.(9) 
2.5.7 Risk factors specific to women 
Several traits related only to women have been examined in their role with BMD.  Researchers 
have found that the association between parity and BMD is likely to be null though it may 
increase the risk of a hip fracture.(35;153)  History of breastfeeding may decrease BMD initially, 
however in the period after cessation women are likely to recover this bone loss.(154;155) Other 
factors not associated with osteoporosis include earlier age of menopause onset, and history of a 
premenopausal oophorectomy.(38;156)  Low levels of endogenous estrogens can increase the 
risk of osteoporosis among women by making calcium maintenance more difficult.(157;158)  
Also, osteoblasts contain estrogen receptors that are highly sensitive to estrogen levels.(159)  In 
addition, estrogen can improve BMD, by increasing OPG and decreasing RANKL production by 
osteoblastic cells, and by suppressing production of TNF-α and other pro-resorptive cytokines, 
estrogen reduces osteoclastogenesis.(160)  Estrogen therapy however has been shown to slow 
bone loss and reduce fracture risk.(161)  However, once discontinued it does not appear to have 
long lasting effects on BMD loss and the risk of fracture.  This is important to consider given the 
adverse effects of long-term estrogen therapy on cardiovascular disease, stroke and breast 
cancer.(162)  
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2.5.8 Risk factors specific to men 
In men, low levels of testosterone have been associated with an increased risk of 
osteoporosis.(163;164)  A cell culture study found androgen receptors on human osteoblast-like 
cells.(165) High Androgen levels may decrease the risk of osteoporosis by promoting osteoblast 
proliferation and differentiation, and inhibiting osteoclast recruitment.(166)  The impact of 
testosterone on the bones may be mediated by aromatization to oestradiol based on case reports 
of osteoporosis in men with mutations in the oestrogen receptor or aromatase genes.(167;168) 
Estrogen therapy on these men had a large effect on the patient's bone growth and 
maturation.(167;168)  Androgen replacement therapy has been shown to increase BMD in some 
studies.(169;170) Studies have also shown that androgen deprivation therapy or surgery to treat 
prostate cancer may result in hypogonadism which can increase an individual’s risk of having 
osteoporosis.(3;171-173) 
2.6 SERUM 25(OH)D AND BONE 
2.6.1 25(OH)D 
Vitamin D is a fat soluble vitamin that comes in 2 major forms, D2 and D3.  Vitamin D2 
(ergocalcifirol) is derived from plants, but is not formed inside the body. Vitamin D3 
(cholecalciferol) is primarily found in animals and can be produced endogenously when 
ultraviolet rays from sunlight strike the skin and trigger vitamin D synthesis.(174)  Few foods 
(fish, mushrooms, egg yolk) naturally contain vitamin D. The vitamin D obtained from sun 
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exposure, food, or supplements is biologically inactive and most undergo hydroxylation to 
become active.  The liver converts vitamin D to 25-hydroxyvitamin D [25(OH)D] followed by 
further hydroxylation in the kidney which results in the physiologically functional 1,25-
dihydroxyvitamin D [1,25(OH)2D] compound. The renal production of 1,25(OH)2D is tightly 
regulated by parathyroid hormone (PTH) levels and serum calcium and phosphorus levels.(175) 
2.6.2 Definition of 25(OH)D deficiency, insufficiency and sufficiency  
There is no clear consensus on what optimal levels of 25(OH)D in the serum are needed.(175)   
Vitamin D deficiency has been defined by most experts as 25(OH)D values of less than 20 ng/ml 
or 50 nmol/l.(176-178) Serum 25(OH) levels have been shown to be inversely associated with 
PTH levels until they reach 30-40 ng/ml or 75-100 nmol/l, at which point PTH levels begin to 
level off.(179;180)  Also, intestinal calcium transport increased by 45 to 65% in women when 25 
(OH)D levels were increased from an average of 20 to 32 ng/ml per or 50 to 80 nmol/l.(12)  
Based on these observations a level of 21-29 ng/ml or 52 to 72 nmol/l can be considered to 
indicate 25(OH)D insufficiency and 30 ng/ml or greater can be defined as having sufficient 
25(OH)D.(181)  However, recent cohort studies in older men and women found that hip fracture 
risk was reduced among participants with 25(OH)D levels >20 ng/ml.(182;183)  In addition, a 
cohort study showed that men with 25(OH)D levels below 20 ng/ml experienced greater hip 
aBMD loss while rates were similar in higher levels.(184)  All of this evidence points to a lower 
25(OH)D threshold than previous research in regards to bone health. 
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2.6.3 25(OH)D levels in men of Caucasian and African descent 
Serum levels of 25(OH)D are generally lower among blacks compared with Caucasian 
individuals in other studies.(185) African Americans typically have lower levels of serum 
25(OH)D than Caucasians across all age groups and both genders (149;185-188) due at least in 
part to differences in skin pigmentation and dietary vitamin D intake.  However, mean 25(OH)D 
concentrations in the African continent are relatively high, but vary considerably according to 
geography, climate, and other factors.(189)  
2.6.4 25(OH)D and bone 
Vitamin D is important for bone growth(10) and preservation.(11) Higher serum 25-
hydroxyvitamin D levels enhance calcium absorption.(12)  Calcium is the structural component 
of the bone and low levels in the body can lead to bone resorption that is directed by the 
PTH.(13)  Without vitamin D, only 10 to 15% of dietary calcium and about 60% of phosphorus 
(another element that consists widely in bone) is absorbed.(175)  Vitamin D deficiency can 
impact bone growth(10) and preservation(11) by increasing the risk of secondary 
hyperparathyroidism and decreasing calcium absorption,  resulting in greater bone turnover, bone 
loss and increased risk of fracture.(14;190)  Adequate vitamin D levels are needed to maintain 
PTH levels and help prevent major bone loss.(15)   Chronic elevations in PTH have been shown 
to have primarily catabolic effects on cortical bone and anabolic effects on trabecular bone.(191)  
In cortical bone, chronic high levels of PTH can result in increased endocortical resorption, 
cortical thinning and cortical porosity.(192;193) Several studies have shown that PTH 
administration and elevated serum PTH levels were associated with preserved trabecular bone 
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structure.(194-198)  PTH is likely to increase trabecular bone by increasing osteoblast bone 
differentiation.(199)  
2.6.5 25(OH)D assays 
The use of different serum 25(OH)D assays has made it difficult to compare studies.  Binkley et 
al. found that they yield markedly different results after comparing radioimmunoassay (RIA) and 
competitive binding protein methods to high performance liquid chromatography (HPLC).(200) 
The use of RIA or competitive binding protein assay has also been shown to overestimate 
25(OH)D levels and have poorer reliability compared to HPLC and  liquid chromatography and 
analysis on a tandem mass spectrometer (LC-MS/MS).(201;202) 
2.6.6 Past studies examining the association between 25(OH)D and bone density, 
geometry and strength measures 
The prospective and cross-sectional findings examining the association between serum 25(OH)D 
and BMD in older men have been inconsistent. Some studies have found a 
positive(15;16;19;203-205) association while others reported null findings.(17;18;206-208)  One 
study examined the effects of vitamin D on bone geometry.(20)  The correlation between 
25(OH) and bone strength measures such as polar/axial moment of inertia or strength strain 
index has not been evaluated.  Few studies have examined the association of 25(OH)D with 
measures of bone health in men of African descent.(16;183;204) The association between higher 
levels of 25(OH)D and greater bone health has been established in Caucasians, however in men 
of African descent there is no clear consensus.  Men of African descent have also been shown to 
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be resistant to the resorptive effects of PTH on bone and markers of bone resorption.(209;210) 
Also, polymorphisms in the vitamin D receptor (VDR) gene may explain this differential 
association.(189) The absence of the BsmI restriction site and the FokI polymorphism for the 
VDR receptor occur at a higher frequency in whites than blacks and were found to be associated 
with lower aBMD.(73;74;77)  Table 2-1 below provides a summary of past findings.  
Table 2-1 Characteristics of studies examining the association between serum 25(OH)D and 
BMD  and geometry, primarily in men 
Authors, Year and 
Journal 
Study Design Study Population Major Findings 
Dennison et al.1999. 
Osteoporos Int. 
 
Longitudinal 
(4 years) 
73 white men and 143 women  
aged 60-75 
Null association for serum 25(OH)D 
and BMD of the lumbar spine and 
femoral neck in men and women. 
Hannan MT et al. 
2000. JBMR 
Longitudinal 
(4 years) 
1164 white men and women mean 
age 74 years 
A null association at all sites 
including femoral neck, trochanter, 
Ward’s area, radius and lumbar spine 
in men and women. 
Szulc P et al. 2003. 
Calcified Tissue Int. 
Cross-
sectional 
881 men aged 19-85 years that 
included 595 men aged 55-85 
years.  
Reported that 25(OH)D levels were 
significantly correlated with BMC 
but not BMD in older men.   
Yan L et al. 2003. 
Bone 
Cross-
sectional 
352 healthy volunteers, 60-83 
years old, were studied in 
Shenyang, China (108 men, 110 
women), and Cambridge, UK (67 
men, 67 women) 
No association was found between 
25(OH)D and BMD.  Marginally 
significant (p=0.05) association 
between femoral BMC and 25(OH)D 
in the UK sample. 
Bischoff-Ferrari HA et 
al. 2004. Am J Med 
Cross-
sectional 
13,432 men and women. Young 
and older white, Mexican 
American, and black 
Men and women with higher 25 
(OH)D levels had higher hip BMD 
for all racial groups. 
Bischoff-Ferrari HA et 
al. 2005. Arthrites and 
Rheumatism  
Cross-
sectional 
A total of 228 subjects (83 men 
and 145 women) mean age 74.4 
years, with primary radiographic 
knee OA. Framingham study. 
In the entire population, there was a 
positive significant trend for femoral 
neck aBMD across categories 
(deficient, hypovitaminosis D, and 
replete) of 25(OH)D, P = 0.04 
Lauretani F et al. 2006. 
Bone.  
Cross-
sectional 
372 Italian men and 435 women, 
aged 65-96 
Cortical and trabecular bone area was 
positively associated with serum 25 
(OH)D (nmol/l) levels in women. 
Saquib et al.2006. 
Osteoporosis Int. 
Cross-
sectional 
Rancho Bernardo study. 414 
Caucasian  men 45 or older 
25(OH)D was positively associated 
with aBMD at the hip (p=0.01) and 
spine (p=0.001) 
Hannan MT et al. 
2008. J Clin 
Endocrinol Metab. 
Cross-
sectional 
331 Black, 362 Hispanic, and 421 
White men from Massachusetts 
with a mean age of 48 years 
A significant association between 
25(OH)D and hip and spinal aBMD 
among Caucasian men only. 
Ensrud KE et al. 2009. 
J Clin Endocrinol 
Metab. 
Longitudinal 
(4 years) 
The Osteoporotic Fractures in 
Men Study, MrOS. 1279 
community-dwelling men aged 65 
yr or older with 25(OH)D levels 
25(OH)D levels below 20 ng/ml had 
greater subsequent rates of hip bone 
loss, but rates of loss were similar 
among men with higher levels 
Kuchuk NO et al. 
2009. J Clin 
Endocrinol Metab.  
Cross-
sectional 
Longitudinal Aging Study 
Amsterdam. 1319 subjects (643 
men and 676 women) ages 65- 88 
A significant association between 
25(OH)D and total hip BMD in men 
and women. 
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2.7 SERUM LEPTIN AND BONE 
2.7.1 Leptin 
Leptin is a hormone secreted by adipose cells that have been shown to impact bone mineral 
density (BMD).(21)  Leptin is a protein molecule secreted by white adipose tissue that is highly 
correlated with body fat mass.(22)  Leptin has been known to be involved in fat metabolism and 
appetite control.(23) Leptin has been shown to play a role in the modulation of bone formation 
by enhancing differentiation of bone marrow stroma into osteoblasts and inhibiting its 
differentiation into osteoclasts and adipocytes.(24;25)   
2.7.2 Leptin and bone 
In vivo studies in mice have shown an increase in  BMD after leptin administration.(211-213)  A 
study in leptin knockout mice showed that BMD increased following administration of 
leptin.(211)  A positive effect on BMD was also observed in another study after administration 
of leptin  prevented the fall in plasma osteocalcin observed during 24-hour and 5-day starvation 
in male mice.(212)  Hemrick et al. found that Leptin treatment induces loss of bone marrow 
adipocytes and increases bone formation in leptin-deficient ob/ob mice.(213)   
         Several in vitro findings reported that higher leptin can have a positive impact on 
BMD.(214-216)  Takahashi et al. showed that leptin induced mitogen-activated protein kinase-
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dependent proliferation of C3H10T1/2 cells and a multipotential stromal murine cell line(215).  
Another study found that leptin was associated with the development of a more mature 
osteoblastic cell line.(214) Also, Thomas et al. observed an increase in osteoblastic 
differentiation of human marrow stromal hMS2-12 cells after leptin administration, which led to 
an increase in the mineralization of the extracellular matrix.(216)    
         Several population studies reported that leptin is positively(34;217-222) associated with 
BMD, while others observed a negative association(223-229), or a null finding after adjusting for 
body weight.(227;230;231)  Few studies have examined the association between leptin and 
fracture.(32;222)  Table 2-2 summarizes some of these findings.     
Table 2-2 Characteristics of studies showing the association between serum leptin, 
fractures and BMD 
Authors, Year and Journal Study 
Design 
Study Population Major Findings 
Martini G et al. 
2001.Bone. 
Cross-
sectional 
123 healthy postmenopausal 
women aged 39-82 years 
After adjustment for BMI, the association 
between leptin and BMD was no longer 
significant 
Pasco et al. 2001. J Clin 
Endocrinol Metab 
Cross-
sectional 
Nonobese Australian women 
aged 20-91 years 
A significant positive association at the 
lateral spine, proximal femur sites, and 
whole body BMD 
Thomas T et al. 2001. 
Bone 
Cross-
sectional 
Sample of 137 premenopausal 
women (21-54 years), 165 
postmenopausal women (34-93 
years), and 343 men (23-90 
years) 
Serum leptin levels were significantly 
associated with hip, spine, and radial aBMD 
in the women, but not in the men.  
Yamauchi M et al. 2001. 
Clin Endocrinol (Oxf) 
Cross-
sectional 
139 postmenopausal women in 
Japan aged 48-78 
Higher leptin levels were associated with a 
lower prevalence of vertebral fractures. 
Blain H et al. 2002. J Clin 
Endocrinol Metab. 
Cross-
sectional 
107 white postmenopausal 
women aged 50-90  
Leptin was associated with whole body and 
femoral neck BMD. 
Ruhl CE et al. 2002. 
JBMR 
Cross-
sectional 
5815 adults from the Third U.S. 
National Health and Nutrition 
Examination Survey (NHANES 
III; 1988-1994 
Inverse association between leptin and BMD 
in men after adjusting for BMI. Null 
associations observed in pre and post 
menopausal women 
Blum M et al.2003. Calcif. 
Tissue Int. 
Cross-
sectional 
153 premenopausal women Leptin was inversely associated with BMD  
Morberg CM et al. 2003. J 
Clin Endocrinol Metab 
Cross-
sectional 
Denmark 327 non-obese men 
and 285 obese men 
Null finding related to BMD in both groups 
non-obese and obese. 
Sun AJ et al. 2003. Acta 
Diabetol. 
Cross-
sectional 
50  healthy men, 18-66 years of 
age 
Leptin ( p=0.004) was negatively associated  
with whole body aBMD 
Zoico et al. 2003. Clin 
Endocrinol (Oxf) 
Cross-
sectional  
A cohort 92 men and 171 
women, of Caucasian descent 
A significant positive association between 
leptin levels, whole-body, total hip and 
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with ages ranging from 68 to 75 
years 
femoral neck BMC and BMD was found in 
both sexes 
Kontogianni MD et 
al.2004. JBMR 
Cross-
sectional 
Twenty-five premenopausal and 
55 postmenopausal, healthy 
women (42-68 years old) 
Leptin levels were negatively correlated with 
BMD of spine and total body only when 
insulin was included in the model 
Schett G et al. 2004. Am J 
Med 
Longitudinal 
(10 years) 
Italy. 125 women and 125 men, 
mean age 58.5 years 
Individuals in the highest tertile for leptin 
had 0.25 times the hazard of having a 
nontraumatic fracture than those in the 
lowest tertile. 
Oh KW et al. 2005. Clin 
Endocrinol (Oxf) 
Cross-
sectional 
80 male adults (mean age 54.5 
years) 
Log-transformed serum leptin showed a 
significant negative correlation with lumbar 
spine BMD after adjusting for age and BMI 
Lorentzon M et al. 
2006.JBMR 
Cross-
sectional 
1068 Swedish young men (aged 
18-20) 
Negative association between leptin and 
areal BMD at the lumbar spine, trochanter 
and total body. 
Weiss LA et al. 2006.J 
Bone Miner Res. 
 
Longitudinal 
(4 years) 
Community-dwelling white men 
(N = 498) and nonestrogen-
using postmenopausal women 
(N= 411), 45–92 years of age 
Leptin associated with greater femoral neck, 
total hip, lumbar spine and radial BMD 
among women at baseline, but not over 4 
years.   
Jurimae J et al. 2008. J 
Bone Miner Metab. 
Cross-
sectional 
Healthy postmenopausal women 
(n = 88; age, 68.9) 
No longer significant association between 
leptin and BMD after adjusting for body 
composition measures 
Jurimae J et al. 2009. Eur J 
Endocrinol. 
Longitudinal 
(1 year) 
35 women (age: 69.7+/-6.0 
years) 
Leptin predicted lower femoral neck and 
total body BMD  
 
Table 2-2 continued. 
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2.8 SERUM ADIPONECTIN AND BONE 
2.8.1 Adiponectin 
Adiponectin is another adipocyte derived hormone that regulates insulin sensitivity and has anti-
inflammatory properties.(26) Unlike leptin, adiponectin levels are lower among individuals with 
obesity.(27)   
2.8.2 Adiponectin and bone 
Adiponectin and its receptors are produced by human bone-forming cells, suggesting that 
adiponectin may be a hormone linking bone and fat metabolism(28).  Adiponectin may have 
harmful effects on bone by stimulating the receptor activator of nuclear factor-κB ligand 
(RANKL) pathway and inhibiting the production of the decoy receptor for RANKL, 
osteoprotegerin.(30) However, adiponectin administration has also been shown to increase 
osteoblast proliferation and differentiation, alkaline phosphatase activity (ALP), a marker of 
bone formation, and mineralization.(30)    
  Several studies reported that lower levels of adiponectin have been linked with higher 
BMD.(33;217;220;232) while others have failed to find an association between adiponectin and 
BMD.(26;225;225;227;229;233-235)  Few studies have examined the association between 
adiponectin and fracture risk.(31;236)  Table 2-3 below summarizes these findings. 
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Table 2-3 Characteristics of studies showing the association between serum adiponectin, 
fractures and BMD 
Authors, Year and Journal Study    Design Study Population Major Findings 
Huang KC et al.2004. Clin 
Endocrinol (Oxf) 
Cross-sectional 105 nondiabetic female 
adolescents mean age 15.4 years 
No association between adiponectin 
and total body BMD and BMC  
Kontogianni MD et 
al.2004. JBMR 
Cross-sectional Twenty-five premenopausal and 
55 postmenopausal, healthy 
women (42-68 years old) 
Adiponectin was not significantly 
correlated with BMD(L2-L4) nor with 
total body BMC 
Oh KW et al. 2005. Clin 
Endocrinol (Oxf) 
Cross-sectional 80 male adults (mean age 54.5 
years) 
Adiponectin was no longer significant 
with femoral neck or lumbar spine 
aBMD after adjusting for age and BMI 
Jurimae J et al. 2007. 
Osteoporos Int. 
Cross-sectional White women aged 38-49 years  Negative association between 
adiponectin and femoral neck and 
lumbar spine BMD.  
Richards JB et al. 2007. J 
Clin Endocrinol Metab. 
Cross-sectional 1735 nondiabetic white women. 
Mean age 50.  
Doubling of serum adiponectin was 
inversely related to a significant mean 
decrease in total hip femoral neck, 
forearm and spine BMD.  
Gonnelli S et al. 2008. 
Calcif Tissue Int 
Cross-sectional 137 men aged 55 years and 
older 
No significant correlations between 
adiponectin and BMD at all skeletal 
sites 
Michaelsson K et al. 2008. 
J Clin Endocrinol Metab 
Longitudinal (15 
years) 
Swedish  men (N=441) and 
women (N=457) aged 70 and 
above 
There was no association between 
lower adiponectin levels and fracture 
risk after finding an inverse 
relationship for BMD 
Jurimae J et al. 2008. J 
Bone Miner Metab. 
Cross-sectional Healthy postmenopausal women 
(n = 88; age, 68.9) 
No longer significant association 
between adiponectin and BMD after 
adjusting for body composition 
measures 
Zoico et al. 2008. J 
Endocrinol Invest 
Cross-sectional Thirty-six post-menopausal non-
diabetic elderly women, with 
ages ranging from 66 to 77 
years 
After adjusting for fat mass only 
adiponectin maintained a significant 
relation with whole body and femoral 
aBMD 
Basurto L et al. 2009. Eur 
J Endocrinol 
Cross-sectional 92 healthy men aged 60-80 
years 
Significant correlations between 
adiponectin and femoral neck and 
spine BMD disappeared after 
adjustment for BMI 
Jurimae J et al. 2009. Eur J 
Endocrinol 
Longitudinal (1 year) 35 women (age: 69.7+/-6.0 
years) 
Lower adiponectin was associated with 
lower spine aBMD loss than greater 
adiponectin 
Kanazawa I et al. 2009. 
Eur J Endocrinol. 
Cross-sectional  231 men and 170 post-
menopausal Japanese women 
with type 2 diabetes 
An increase in one standard deviation 
of adiponectin was associated with 
higher odds of vertebral fracture in 
men but not women.   
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2.9 SPECIFIC AIMS 
The aim of Research Article 1 was to better understand and evaluate if correlates of trabecular 
and cortical vBMD differ in older men of primarily Caucasian descent.  The potential correlates 
included demographic characteristics, anthropometric measures, lifestyle factors and medical 
history. 
 The aim of Research Article 2 was to better understand and determine if the associations 
between serum 25(OH)D and measures of bone quality differ among men of Caucasian and 
African descent.  We also sought to identify approximate 25(OH)D thresholds at which there is 
greater bone quality.  
The aim of Research Article 3 was to test the hypothesis that higher serum leptin and 
lower adiponectin will decrease the risk of a fracture and predict lower hip aBMD loss in men 
and women of Caucasian and African American descent.   
We used longitudinal and cross-sectional data from the osteoporotic fractures in men 
study (MrOS), the Tobago Bone Health Study, and the health aging and body composition study 
(ABC) to perform analyses for these three research manuscripts.  These observational cohort 
studies are based upon large community based populations of primarily older residents.   
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3.1 ABSTRACT 
Quantitative computed tomography (QCT) can estimate volumetric bone mineral density 
(vBMD) and distinguish trabecular from cortical bone. Few comprehensive studies have 
examined correlates of volumetric bone mineral density (vBMD) in older men.  This study 
evaluated the impact of demographic, anthropometric, lifestyle, and medical factors on vBMD in 
1172 men, aged 69-97, and enrolled in The Osteoporotic Fractures in Men Study (MrOS).  
Peripheral quantitative computed tomography (pQCT) was used to measure vBMD of the radius 
and tibia.  The multivariable linear regression models explained up to 10% of the variance in 
trabecular vBMD and up to 9% of the variance in cortical vBMD.  Age was not correlated with 
radial trabecular vBMD.  Correlates associated with both cortical and trabecular vBMD were age 
(-), caffeine intake (-), total calcium intake (+), non-trauma fracture (-), and hypertension (+).  
Higher body weight was related to greater trabecular vBMD and lower cortical vBMD. Height (-),
education (+), diabetes with TZD use (+), rheumatoid arthritis (+), using arms to stand from a    
chair (-), and anti-androgen use (-) were only associated with trabecular vBMD.  Factors only 
associated with cortical vBMD included clinic site (-), androgen use (+), grip strength (+), past 
smoker (-) and time to complete 5 chair stands (-).  Certain correlates of trabecular and cortical 
volumetric BMD differed among older men.  An ascertainment of risk factors associated with 
trabecular and cortical vBMD may lead to better understanding and preventive efforts for 
osteoporosis in men.   
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3.2 INTRODUCTION 
There is growing recognition that osteoporosis and fractures in older men are significant public 
health problems that contribute to disability and premature death.(1)  Osteoporosis is defined as a 
systemic bone disease characterized by low bone mass and mircoarchitectural deterioration of 
bone tissue, with a subsequent increase in bone fragility and susceptibility to fracture.(2)  Low 
bone mineral density (BMD) is an important risk factor for fractures in men.  Men over the age 
of 50 have a 13% estimated risk of developing an osteoporotic fracture.(3)  
One major limitation of dual x-ray absorptiometry (DXA) is its inability to distinguish 
cortical and trabecular bone.  Bones tend to differ in their composition of trabecular and cortical 
bone.  For example, the spine is almost entirely trabecular bone.(4)  Therefore, identifying 
correlates of trabecular bone can lead to a better understanding of what factors might be 
associated with spine fracture.  Also, DXA only provides a measurement in 2-dimensions and 
thus reports an “areal” BMD (aBMD).  Bones of larger width and length tend to have greater 
depth (e.g., in men compared to women), and since bone depth is not accounted for in DXA 
scanning, reliance on aBMD inherently underestimates bone density.(5)  Volumetric bone 
mineral density (vBMD) has been shown to be a stronger predictor of vertebral fractures than 
aBMD in some studies.(6;7)  Quantitative computed tomography (QCT) assesses vBMD and 
distinguishes cortical from trabecular bone.(8) The correlates of DXA-measured BMD have been 
well established in men.(1;9-13) However, few studies have examined the correlates of vBMD, 
especially in older men.(8;11)  The aim of this study was to identify correlates of trabecular and 
cortical vBMD using peripheral quantitative computed tomography (pQCT) and examine if they 
differ.   
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3.3 METHODS 
3.3.1 Study population 
From March 2000 through April 2002, 5,995 men aged 65 years or older, were recruited using 
population-based listings from six US clinical sites to participate in the Osteoporotic Fractures in 
Men Study, “MrOS”.(14;15)  Peripheral QCT measurements were obtained at the Minneapolis, 
MN and Monongahela Valley, PA study sites during the second clinic visit between March 21, 
2005 and April 11, 2006, for 1172 individuals (46.1% from MN, and 53.9% from PA), aged 69-
97.  The institutional review board (IRB) at each center approved the study protocol, and written 
informed consent was obtained from all the participants. 
3.3.2 Peripheral QCT  
Peripheral QCT examinations were performed on the Sratec XCT scanner series (2000, or 3000). 
Trabecular vBMD of the radius and tibia was measured by obtaining an ultra distal slice at 4% 
the length of the ulna proximal to the radial endplate and at 4% of the tibia length proximal to the 
tibial endplate, respectively.  Cortical vBMD of the radius and tibia was measured by obtaining a 
distal slice at 33% the length of the ulna proximal to the radial endplate and at 33% of the tibia 
length proximal to the tibial endplate, respectively.  A scoutview (an anatomic reference line for 
the relative location of subsequent scans) was obtained prior to the pQCT scan at the tibia and 
radius.  Precise assessment of bone mineral properties by pQCT was assured by minimizing 
participant movement.  A quality assurance (QA) phantom scan was used to monitor the stability 
31 
 
of the pQCT scanner.  A cross-calibration check was also performed between the centers. The 
European Forearm Phantom was scanned 3 times at each site at 200, 100 and 50 mg/cc, 
respectively.  Voxel size was 0.5 mm and the scan speed was 25 mm/s.  To determine the 
trabecular (mg/cm3) vBMD, all radius and tibia scans were analyzed using identical parameters 
for contour findings and separation of trabecular and cortical bone (contour mode 2, T=169 
mg/cm3; peel mode 1, area=45%).  All proximal radius and tibia shaft scans were analyzed using 
identical parameters for contour finding and separation of total and cortical bone (contour mode 
2, T=169 mg/cm3;cortmode 1, T=710 mg/cm3) to determine the vBMD of the cortical (mg/cm3) 
rich bone compartment.  Coefficients of variation (CV) were determined for pQCT scans by 
replicating measurements on 15 subjects (CV ≤ 2.1%).(8) 
3.3.3 Other measurements  
 Self-administered and interviewer administered questionnaires were used by trained clinical 
staff to obtain demographic, medical and lifestyle information from the participants.  Information 
on anthropometric measures, neuromuscular function, and medication use was also obtained at 
the clinic.(14) 
Information on covariates were obtained from visit 2, with the exception of  
race/ethnicity, education, alcohol intake, calcium and vitamin D intake, history of a non-trauma 
fracture after the age of 50, self-report of diabetes and fasting glucose level, whether a subject 
ever had a gastrectomy, and testosterone injection use which were abstracted at baseline.   
Race or ethnicity was determined by self-declaration and included these categories: 
Caucasian, African American, Hispanic, Asian, and other.  The participants were divided into 2 
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categories of education for analysis: greater than a high school education and high school 
education or lower.   
A calibrated balance beam scale was used to measure weight in kilograms (kg).  
Participants had to wear indoor clothing and remove their shoes when their weight was being 
measured.  Height was measured in meters (m) using a Harpenden Stadiometer (Dyfed, UK).   
Gait speed (m/s) was determined as the time to complete a six meter walk.  Grip strength 
(kg) was measured twice using a handheld dynamometer (Jamar) and taking the average in both 
right and left arms.  Time to complete 5 chair stands (seconds) and ability to stand from a chair 
without using arms (yes/no) were also measured.     
Lifestyle factors include the self-report of smoking (current, past and never), alcohol 
intake (drinks/week), caffeine intake (mg/day), and time spent walking (hours/day).  Overall 
physical activity was also measured by computing the physical activity summary scale for the 
elderly (PASE).(16)  The modified Block Food Frequency Questionnaire was used to obtain 
dietary information related to calcium and vitamin D intake over the past year. (17)   
 Subjects were asked to report if they were ever told by a doctor, or health care provider, 
that they had certain medical conditions including hypertension, stroke, myocardial infarction 
(MI), chronic obstructive pulmonary disease (COPD), cancer, osteoporosis, osteoarthritis (OA), 
hyperthyroidism, hypothyroidism, Parkinson’s disease, and kidney stones.  Men were classified 
as having diabetes if they had glucose levels >126 mg/dl (after minimum of an 8 hour fast) at 
baseline, self-report of diabetes at baseline or visit 2, or reported taking insulin or hypoglycemic 
medications at baseline or visit 2.  Men with diabetes were further categorized as having a 
history thiazolidinedione (TZD) versus non-TZD use. We are unable to distinguish type 1 and 2 
diabetes.  However, based on the older age of the participants and the shorter longevity 
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associated with type 1 diabetes for this birth cohort, it is likely that nearly all have type 2 
diabetes. 
        Participants were asked to bring all current (within last 30 days) prescription and nonprescription 
medications with them to clinic.  Interviewers completed a medication history for each participant, 
including name of medication and frequency of use.  All prescription medications recorded by the clinics 
were stored in an electronic medications inventory database (San Francisco Coordinating Center, San 
Francisco, CA). Each medication was matched to its ingredient(s) based on the Iowa Drug Information 
Service (IDIS) Drug Vocabulary (College of Pharmacy, University of Iowa, Iowa City, IA).(18)   
Androgen use was defined as testosterone or dehydroepiandrosterone (DHEA) use. Anti-androgen use 
included use of flutamide or bicalutamide.   
3.3.4 Statistical analysis 
All statistical analyses were performed using the Statistical Analysis System (SAS, version 9.1; SAS 
Institute, Cary, NC).  Analysis of variance (ANOVA) was used to compare the unadjusted skeletal site-
specific vBMD across age groups with a test of trend and a Bonferroni adjustment for pairwise 
comparisons.  Linear regression analyses for age and age and weight adjusted models were used to 
examine the association of each correlate with cortical and trabecular vBMD at the radius and tibia.  The 
associations were expressed as a one unit increase for categorical variables and one standard deviation 
(SD) increase for continuous variables.  The formula used to calculate the percent difference in vBMD 
per unit change of predictor variable was: (β coefficient*unit/mean vBMD)*100.  The corresponding 
confidence intervals were calculated as: [(β coefficient ± 1.96*standard error)*(unit)/ (mean 
vBMD)*100].  Variables with a p-value less than 0.10 from the age and weight- adjusted models were 
entered into the multivariable models.  We excluded men from the multivariable analysis who reported 
taking osteoporosis medication (n=42) or self-reported osteoporosis (n=41), since these men on average 
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had markedly lower vBMD compared with non-users.  For the multivariable models, we used the 
backward elimination procedure at each skeletal site with age forced in the models.  Stepwise selection 
procedure produced similar results.  Multi-collinearity was assessed using the variance inflation factor 
(VIF).  An additional analysis examined if correlates of vBMD differed after excluding non-white men in 
the multivariable analysis. To further understand if the association between diabetes and vBMD is 
independent or modified by hypoglycemic medication use, we performed secondary multivariable 
analyses with and without (diabetic versus non-diabetic) taking into account diabetic medications.  For 
the diabetes medications parameter men were categorized as: non-users of hypoglycemic medication; 
insulin or hypoglycemic use without a history of TZD use; and any TZD use either with or without 
additional hypoglycemic medications.   
3.4 RESULTS 
The study population consisted of Caucasians (97.9%), African Americans (1.4%), Asians 
(0.2%), Hispanics (0.3%), and other (0.2%).  The average age of the men was 77.2 ± 5.1 years 
and 61.9% had higher than a high school education. The mean and SD values for trabecular and 
cortical vBMD were 197 ± 46 mg/cm3 and 1159 ± 34 mg/cm3, respectively for the radius and 
were 231 ± 41 mg/cm3 and 1136 ± 35 mg/cm3, respectively for the tibia. Tables 3-1 and 3-2 
show the age and age and weight adjusted models.  These results were used to build the 
multivariable models. 
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3.4.1 Pairwise comparisons of trend for vBMD by age  
 Figure 3-1 and 3-2 show the unadjusted cross-sectional age-related patterns at each site.  
Trabecular vBMD at the radius did not differ by age (p for trend=0.483).  The test of linear trend 
for tibial trabecular vBMD was statistically significant (p=0.002).  Participants aged 69-74 had 
4.1% and 5.7% greater trabecular vBMD at the tibia than those aged 80-84 (p=0.022) and 85+ 
(p=0.030), respectively.  Cortical vBMD varied by age at both skeletal sites (p for trend <0.001).    
At the radius men aged 69-74 had 0.7% and 1.8% greater cortical vBMD than those aged 80-84 
(p=0.008) and 85+ (p<0.001), respectively.  Radial cortical vBMD was 1.5% greater among 
participants aged 75-79 than men aged 85+ (p<0.001).  Also, men aged 80-84 had 1.0% greater 
radial cortical vBMD than those aged 85+ (p=0.021).  At the tibia, men aged 69-74 had 0.9% and 
1.1% greater cortical vBMD than those aged 80-84 (p=0.001) and 85+ (p=0.005), respectively.  
Finally, those aged 75-79 had 0.7% greater tibial cortical vBMD than men aged 80-84 (p=0.035).  
3.4.2  Multivariable models 
 The results of the multivariable analyses are summarized in table 3-3. At the radius, 
multivariable models explained 4 and 9% of the overall variance for trabecular and cortical 
vBMD, respectively. The models for cortical and trabecular vBMD at the tibia site explained 8% 
and 10% of the overall variance.  An increase of one SD (5.1 years) of age was significantly 
correlated with lower vBMD all sites with the exception of the trabecular vBMD at the radius.  
Having greater than a high school education was correlated with 3.0% greater trabecular vBMD 
of the tibia.  Men from Monongahela Valley had -0.8% lower cortical vBMD than those from 
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Minneapolis.  A one SD (13.5 kg) increase in weight was associated with 2.3% greater tibial 
trabecular vBMD.  However, this increase in weight was correlated with lower cortical vBMD of 
the radius (-0.5%) and tibia (-0.3%).  One SD (6.9 cm) increase in height was associated with 
lower trabecular vBMD at the tibia (-1.6%).  One SD (259.3 mg/day) increase in caffeine was 
associated with lower cortical vBMD of the radius.  Caffeine intake was also associated with 
lower trabecular and cortical vBMD of the tibia.  A SD (564.9 mg/day) increase in total calcium 
was associated with greater cortical and trabecular vBMD at both skeletal sites.  Past smokers 
had significantly lower (-0.4%) cortical vBMD of the radius than individuals who had never 
smoked.  History of a non-trauma fracture was associated with lower trabecular and cortical 
vBMD at both sites.  Men who had diabetes and used TZD had greater trabecular vBMD of the 
radius (9.3%) and tibia (8.0%) than those with no diabetes.  Having hypertension was correlated 
with greater (4.9%) trabecular and cortical (0.6%) vBMD of the radius.  RA was associated with 
a 5.3% greater trabecualar vBMD of the tibia.  Androgen use was correlated with greater cortical 
vBMD at both sites.  Men who used anti-androgens had lower (-24.9%) trabecular vBMD of the 
tibia.  An increase of one SD (7.7 kgs) in grip strength was associated with greater (0.3%) 
cortical vBMD of the radius.  Each SD (3.4 second) increase in time to complete five chair 
stands was associated with lower (-0.3%) cortical vBMD at the tibia.  Men who need to use their 
arms to stand from a chair had lower (-7.2%) trabecular vBMD of the tibia.  
3.4.3 Secondary Analyses 
In the analysis that did not account for hypoglycemic medication use, men identified as having 
diabetes did not differ significantly by vBMD compared to men without DM.  Insulin or 
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or hypoglycemic use in our study population of older men was not correlated with BMD  
of the radius or tibia.  However, older men who used TZDs had significantly greater radial (8.9%)
and tibial (9.6%) trabecular BMD than nonusers of anti-diabetic medication in MrOS. Also
exclusion of non-whites from the multivariable analysis did not change correlates identified.   
3.5 DISCUSSION 
We chracterized demographic, anthropometric, lifestyle, and medical factors to understand their 
association with cortical and trabecular vBMD among older men.  Unique features of this study 
include large sample size of men, comprehensive nature of the analyses and ascertainment of 
correlates and outcome.  Our study results suggest that some correlates of trabecular vBMD may 
differ from those of cortical vBMD.   
Age was not associated with lower radial trabecular (ultra-distal) vBMD, consistent with 
findings of a previous study by Dalzell et al.(19) but contrary to the findings of Riggs et 
al.(20;21)  Reduction in trabecular vBMD has been shown to occur before mid-life (age 20-49) 
in men and women and continue unabated through life.(20-22)  The mechanism for this early 
onset of trabecular vBMD loss remains unknown. A significant reduction in radial trabecular 
vBMD may have occurred at a younger age for this population.  However, our results are cross-
sectional comparisons across age groups and longitudinal studies are needed.  Consistent with 
prior findings, increasing age was associated with lower cortical vBMD.(19-21;23)  In women, 
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substantial cortical bone loss has been shown to occur after mid-life in association with 
menopause and estrogen deficiency.(24)  However, cortical bone loss in men seems to decrease 
at a constant rate in young adulthood until accelerating late in life.(21)   
This report showed a positive association between education and trabecular vBMD.  This 
correlation has not been previously reported in men and may be a result of residual confounding.  
Higher education may lead to the adoption of a better lifestyle that could impact vBMD 
positively.       
Body weight was associated with greater trabecular vBMD, consistent with two 
previous studies.(8;25) Several studies observed a positive association between weight and 
aBMD.(9;10;13)  Larger skeletal frames and greater muscle and body fat in heavy individuals 
may increase the mechanical load on the skeleton promoting mineralization and structural 
adaptive responses that can strengthen bone.(26)  However, body weight was associated with 
lower cortical vBMD similar to two previous studies.(8;27) It is also possible that mechanical 
factors or differences in bone geometry may explain these findings.  Paradoxically, increased 
mechanical loads can lead to bone microdamage, increased bone turnover, and a transient 
reduction in cortical vBMD.(28) Also, overweight individuals may adapt by increasing periosteal 
bone diameter requiring lower cortical density to maintain the same strength.(29)  Additional 
studies are needed to fully understand these relationships. 
 Similar to our findings, the Tobago Bone Health Study reported a negative association 
between height and trabecular vBMD, consistent with the negative association on femoral neck 
aBMD.(1;8)  Taller individuals are known to experience greater height loss and have been shown 
to be at a higher risk of fracture than others.(30-32)   
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Several lifestyle and dietary variables were correlated with vBMD.  Higher caffeine 
intake was associated with lower cortical and trabecular vBMD, similar to a previous study that 
examined calcaneus BMD in a young population of primarily Caucasian men.(25)  However, 
some studies on aBMD in older Caucasian men (1;9;10) and another on vBMD in African men 
found no association.(8) Caffeine may reduce BMD by decreasing intestinal calcium absorption 
but it may also be a marker for lower calcium consumption in our population(r=-0.1, 
p=0.059).(33)  Our study found that past smokers had significantly lower cortical vBMD.  A 
study on men of African descent found a negative correlation among smokers for trabecular and 
cortical vBMD(8) and another found a negative association among smokers for trochanter aBMD 
in a cohort of primarily elderly Caucasian men.(10)  However, The Gothenburg Osteoporosis 
and Obesity Determinants (GOOD) failed to find a significant association between smoking and 
vBMD.(34)  Smoking has been shown to have a  negative effect on BMD by decreasing calcium 
absorption or by inhibiting the proliferation of osteoprogenitor cells.(35;36)  Total calcium use 
was associated with greater trabecular and cortical vBMD which is consistent with studies on 
aBMD(1;12) and vBMD(25) in Caucasian men and another in African men(8).  An adequate 
intake of calcium is needed to ameliorate the progressive loss of bone with age.(37)   
History of fracture was one of the strongest variables related to lower trabecular and 
cortical vBMD at both skeletal sites and is consistent with studies of aBMD(1;13) and 
vBMD(23;38;39) in men. Diabetic men using TZD medication had greater trabecular vBMD at 
both skeletal sites.  Greater weight among TZD users compared to diabetic men with no TZD use 
(95.3 kg vs. 88.5 kg, p=0.013) and non-diabetic men (95.3 kg vs. 82.9 kg, p<0.001) may have 
contributed to these findings.  Prior research shows a negative association between TZD use and 
aBMD in diabetic men and women(40;41) consistent with the observation that TZDs increase 
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bone marrow adiposity resulting in a decrease in osteoblastogenesis, and possibly affect the 
aromatase pathway leading to a reduction in estrogen production(42;43).  Our findings are 
surprising and need to be replicated in other studies.  Hypertension was associated with higher 
trabecular and cortical vBMD comparable to previous studies for aBMD(1) in Caucasian men 
and vBMD in men of African heritage.(11)  However, Orwoll et al. reported that hypertension 
was related to lower aBMD in a largely Caucasian population of men aged 60 and older.(13)  A 
positive association may arise from confounding by the use of certain medications such as 
thiazide (TZ) diuretics that may increase BMD due to their ability to improve calcium 
retention.(9;44;45)  However, excluding TZ diuretic users did not change the association, 
making it likely that other factors were involved.  RA was unexpectedly associated with greater 
cortical vBMD of the radius and may have occurred by chance.  An earlier report using the same 
cohort found no association between RA and aBMD(1) while another study found a negative 
correlation among older Caucasian men.(13) Anti-inflammatory medications such as non-
steroidal anti-inflammatory drugs (NSAIDs) have been shown to increase BMD.(1;46) 
Excluding men who used NSAIDs attenuated the association making it no longer significant.      
Androgen replacement use was associated with higher cortical vBMD at both sites, 
consistent with past findings, that assessed trabecular vBMD (47), and aBMD(48), of the  
lumbar spine.  High androgen levels may help maintain BMD by promoting osteoblast 
differentiation, and inhibiting osteoclast recruitment.(49)  The very low prevalence (0.6%) of 
androgen users likely contributed to the null finding for trabecular vBMD. Anti-androgen use 
was independently related to lower trabecular vBMD of the tibia. The Tobago Bone Health 
Study also found that anti-androgen users had significantly lower cortical vBMD at the radius 
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and tibia.(8)  Androgen deprivation therapy or surgery to treat prostate cancer may result in 
hypogonadism which is associated with lower BMD.(50;51) 
 The negative association between poor neuromuscular function and lower vBMD was 
documented in several studies.(1;23;52) Although the mechanism for this association is not 
entirely clear, it may be due to the lower skeletal loading that occurs as a result of having  
weaker muscles.(53)  Lower grip strength was associated with lower cortical vBMD at the radius 
consistent with past reports on aBMD(1) and vBMD(23) in Japanese men.  Our study also found 
a negative association between using arms to stand from a chair and lower trabecular vBMD, 
similar to a study in this cohort on aBMD.(1)   
Our multivariable models explained up to 10% of the variance in trabecular vBMD and up 
to 9% of the variance in cortical vBMD.  These estimates are slightly lower than findings on 
aBMD(1;9;13), but compare well to similar studies on vBMD(8;11;19;25) in men.  A possible 
explanation for this observation may be that aBMD is a combination of density, size and 
geometry of both cortical and trabecular bone, while vBMD in our study reflects the density of 
the voxels in the cortical or trabecular bone.  These results suggest that there are unknown 
factors, possibly genetic, related to vBMD in older men that we have yet to identify.  Fewer 
correlates were identified for trabecular vBMD of the radius when compared to tibial trabecular 
vBMD.  The tibia is a major weight bearing site compared to the radius so variables such as 
weight and physical function may exert a greater influence on vBMD.   
This study had several potential limitations.  Based on the cross-sectional nature of this 
study design, causality cannot be established because we are unable to determine temporal 
relationships between the variables.  Many of the variables were collected through self-report so 
there was potential for recall bias resulting in misclassification. African Americans are known to 
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have higher aBMD(1;58) and central vBMD(59) than Caucasians. It is likely that the small 
number of African Americans (1.4%) in our sample reduced our potential to detect an 
association.  Other findings may also have been impacted by lower power (e.g., current smokers 
(2.9%)). Despite statistical significance, the clinical significance of some of the findings is 
questionable due to low percentage differences in vBMD.   
In summary, we determined that correlates of trabecular and cortical vBMD differed in 
our large cohort of older men. Bones vary in their composition with some primarily made of 
cortical bone and others that are almost entirely trabecular bone.  An ascertainment of risk 
factors associated with trabecular and cortical vBMD may lead to better understanding and 
preventive efforts for osteoporosis in men.  Our study also adds to the growing literature on the 
inverse association between body weight and cortical vBMD.  Longitudinal studies are needed to 
better understand the mechanisms underlying these differential associations.                
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 Figure 3-1 Trabecular vBMD by age 
 
 
 
Figure 3-2 Cortical vBMD by age  
3.7 TABLES AND FIGURES
48 
 
Table 3-1 Percent difference in trabecular and cortical vBMD of the radius per unit change in potential correlates for age and age and weight adjusted models. 
Percent difference in vBMD per unit change (95% CI) Variable Mean ± SD or 
Prevalence 
 
Unit 
Age 
Adjusted 
Trabecular vBMD 
Age and 
Weight 
Adjusted 
Trabecular 
vBMD 
Age 
Adjusted 
Cortical 
vBMD 
Age and Weight 
Adjusted 
Cortical 
vBMD 
  Demographics       
  Age (years) 77.2 ± 5.1 5.1 -0.8 (-2.1, 0.6) ++ -0.3 (-1.8, 1.1) -0.5 (-0.7, -0.3)* -0.6 (-0.5, -0.1)* 
  Race       
  Caucasian 97.9%  _ _ _ _ 
  African-American 1.4%  -8.3 (-20.3, 3.7) -7.8 (-19.8, 4.1) -0.9 (-2.4, 0.5) -1.0 (-2.5, 0.4) 
  Asian 0.2%  -19.2 (-51.7, 13.3) -16.7 (-49.3, 15.9) -0.9 (-3.1, 5.0) 0.4 (-3.7, 4.4) 
  Hispanic 0.3%  -11.6 (-34.7, 11.4) -12.2 (-35.2, 10.8) -0.7 (-3.6, 2.1) -0.6 (-3.5, 2.2) 
  Other 0.2%  18.1 (-14.5, 50.6) 18.0 (-14.5, 50.5) 3.9 (-1.2, 7.9)** 3.9 (-0.1, 7.9)** 
  >High School Education 61.9%  -0.3 (-3.1, 2.5) -0.3 (-3.1, 2.6) 0.5 (0.1, 0.8)* 0.5 (0.1, 0.8)* 
  Site 
  Monongahela Valley, PA 
 
53.9% 
  
-0.3 (-3.1, 2.4) 
 
0.3 (-3.0, 2.5) 
 
-0.3 (-0.1, 0.6) 
 
-0.3 (-0.1. 0.6) 
  Anthropometry       
  Weight (kg) 83.9 ± 13.5 13.5 1.6 (0.2, 3.0) +++,* 1.5 (0.1, 2.9)* -0.2 (-0.3, 0.0) +++,** -0.3 (-0.5, -0.1)* 
  Height (cm) 173.0 ± 6.9 6.9 -0.5 (-1.9, 0.9) -1.4 (-3.0, 0.1)** 0.0 (-0.1, 0.2) 0.2 (0.0, 0.4)* 
  Lifestyle       
  Smoking 
  Never 
  Past 
  Current 
 
36.2% 
60.9 % 
2.9% 
  
_ 
-3.4 (-6.3, -0.6)* 
-7.5 (-15.7, 0.7)** 
 
_ 
-3.8 (-6.7, -0.9)* 
-7.4 (-15.6, 0.8)** 
 
_ 
-0.6 (-1.0, -0.3)* 
-0.7 (-1.7, 0.3) 
 
_ 
-0.6 (-0.9, -0.2)* 
-0.7 (-1.7, 0.3) 
  Caffeine intake (mg/day) 261.4  ± 259.3 259.3 -1.4 (-2.7, -0.0)* -1.4 (-2.8, -0.0)* -0.2 (-0.4, 0.0)* -0.2 (-0.4, -0.0)* 
  Alcohol (drinks/week) 3.7 ± 6.8 6.8 -0.7 (-2.1, 0.6) -0.8 (-2.2, 0.5) -0.1 (-0.3, 0.1) -0.1 (-0.3, 0.1) 
   Physical activity (PASE) 141.4 ± 65.9 65.9 0.0 (-1.4, 1.4) 0.2 (-1.2, 1.6) 0.2 (-0.0, 0.3)** 0.1 (-0.1, 0.3) 
  Walk for exercise (hrs/d) 1.8  ± 0.8 0.8 -0.9 (-2.3, 0.6) -0.8 (-2.2, 0.7) -0.0 (-0.2, 0.2) -0.0 (-0.2, 0.2) 
   Supplemental calcium intake (mg/d) 278.3 ± 389.6 389.6 0.5 (-0.8, 1.9) 0.7 (-0.7, 2.0) 0.2 (0.0, 0.4)* 0.2 (0.0, 0.3)* 
   Total calcium (mg/d) 1126.7  ± 564.9 564.9 2.0 (0.6, 3.3)* 2.0 (0.7, 3.4)* 0.3 (0.1, 0.4)* 0.3 (0.1, 0.4)* 
   Daily vitamin intake (IU/d) 172.8 ± 123.2 123.2 1.2 (-0.2, 2.6) 1.2 (-0.2, 2.5) 0.0 (-0.1, 0.2) 0.1 (-0.1, 0.2) 
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   Medical History       
   Non-Trauma fracture since age 50 15.3%  -7.1 (-10.9, -3.3)* -7.2 (-10.9, -3.4)* -1.0 (-1.4, -0.5)* -0.9 (-1.4, -0.5)* 
   No diabetes 80.9%  - - - - 
   Diabetes and non-TZD use 
   Diabetes and TZD use 
15.8% 
3.3% 
 3.0 (-0.8, 6.8) 
10.8 (3.0, 18.4)* 
3.9 (-1.3, 6.4) 
9.8 (2.0, 17.6)* 
-0.3 (-0.7, 0.2) 
-0.0 (-1.0, 0.9) 
-0.1 (-0.6, 0.3) 
0.2 (-0.7, 1.2) 
   Hypertension 52.8%  5.1 (2.3, 7.8)* 4.8 (2.0, 7.5)* 0.3 (-0.0, 0.7)** 0.4 (0.1, 0.8)* 
   MI 17.1%  1.0 (-2.6, 4.7) 1.0 (-2.6, 4.7) 0.0 (-0.5, 0.5) 0.0 (-0.4, 0.5) 
  Stroke 6.9%  2.4 (-3.0, 7.9) 2.2 (-3.2, 7.7) 0.2 (-0.5, 0.9) 0.3 (-0.4, 1.0) 
  Cancer 30.3%  0.0 (-3.0, 3.0) 0.0 (-3.0, 3.0) -0.2 (-0.5, 0.2) -0.2 (-0.6, 0.2) 
  Osteoporosis 3.5%  -15.8 (-23.2, -8.5)* -15.4 (-22.7, -8.0)* -2.1 (-3.1, -1.2)* -2.3 (-3.2, -1.4)* 
  Rheumatoid Arthritis 6.1%  1.6 (-4.3, 7.5) 1.2 (-4.7, 7.1) -0.6 (-1.3, 0.1) -0.5 (-1.2, 0.2) 
  Osteoarthritis 22.5%  1.1 (-2.2, 4.4) 1.1 (-2.2, 4.3) 0.1 (-0.3, 0.5) 0.1 (-0.3, 0.5) 
  Hyperthyroid 2.5%  1.3 (-7.3, 10.0) 1.2 (-7.5, 9.8) 0.1 (-1.0, 1.2) 0.1 (-0.9, 1.2) 
  Hypothyroid 6.4%  2.0 (-3.5, 7.5) 2.1 (-3.4, 7.6) 0.1 (-0.6, 0.8) 0.1 (-0.6, 0.8) 
  COPD 10.1%  -4.0 (-8.5, 0.6)** -4.1 (-8.6, 0.5)** -0.5 (-1.1, 0.1)** -0.5 (-1.1, 0.1)** 
  Parkinson’s 1.1%  -12.7 (-27., 1.9)** -12.5 (-27.1, 2.1)** -0.8 (-2.6, 1.0) -0.8 (-2.6, 1.0) 
  Gastrectomy 5.5%  -2.0 (-8.0, 3.9) -2.0 (-7.9, 4.0)** -0.6 (-1.4, 0.1)** -0.7 (-1.5, -0.1)* 
  Kidney stones 13.3%  -3.2 (-7.2, 0.8) -3.4 (-7.4, 0.7) -0.1 (-0.6, 0.4) -0.1 (-0.6, 0.4) 
  Medications       
  Androgens 0.6%  6.8 (-10.7, 24.2) 5.7 (-11.8, 23.1) 2.8 (0.7, 5.0)* 3.1 (0.9, 5.2)* 
  Testosterone injections 0.5%  7.1 (-11.8, 25.9) 6.2 (-12.6, 25.0) 1.4 (-1.0, 3.7) 1.6 (-0.8, 3.9) 
  Anti-androgen use 0.5%  -8.1 (-27.0, 10.7) -8.1 (7.7, -23.9) -3.2 (-5.5, -0.9)* -3.2 (-5.5, -0.9)* 
  Cox-II inhibitors 2.0%  -4.9 (-14.6, 4.8) -4.8 (-14.5, 4.9) -0.1 (-1.3, 1.2) -0.1 (-1.3, 1.1) 
  NSAID use 16.2%  -1.1 (-4.8, 2.6) -1.5 (-5.2, 2.2) -0.3 (-0.7, 0.2) -0.2 (-0.6, 0.3) 
  Thiazide diuretic use 19.0%  3.3 (-0.2, 6.8)** 3.0 (-0.5, 6.5)** 0.3 (-0.1, 0.8) 0.4 (-0.0, 0.9)** 
  Non-thiazide  diuretic use 11.8%  2.7 (-1.6, 7.0) 2.1 (-2.3, 6.4) -0.1 (-0.6, 0.4) 0.0 (-0.5, 0.6) 
  Loop diuretics use 7.5%  2.5 (-2.8, 7.9) 1.7 (-3.7, 7.1) -0.4 (-1.0, 0.3) -0.2 (-0.8, 0.5) 
  Statins 45.2%  2.0 (-0.8, 4.8) 1.9 (-0.9, 4.6) 0.3 (-0.1, 0.6) 0.3 (-0.1, 0.6) 
  Nitrates 6.5%  2.3 (-3.3, 7.9) 2.2 (-3.4, 7.8) 0.6 (-0.1,1.3) 0.6 (-0.1, 1.3) 
  Beta blockers 33.3%  1.4 (-1.5, 4.3) 1.2 (-1.7, 4.1) 0.2 (-0.2,0.5) 0.2 (-0.1, 0.6) 
  Anti-convulsants 3.4%  1.6 (-6.0, 9.2) 1.6 (-6.0, 9.2) -0.6 (-1.6, 0.3) -0.6 (-1.6, 0.3) 
  SSRI use 4.3%  4.3 (-2.5, 11.1) 4.0 (-2.8, 10.8) 0.3 (-0.6, 1.1) 0.3 (-0.5, 1.2) 
  Tricyclic antidepressants 1.1%  1.0 (-11.8, 13.9) 0.1 (-12.7, 13.0) 1.1 (-0.5, 2.7) 1.3 (-0.3, 2.9) 
Table 3-1 continued. 
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  Thyroid hormone use 8.4%  1.3 (-3.6, 6.3) 1.3 (-3.6, 6.3) 0.3 (-0.3, 0.9) 0.3 (-0.3, 0.9) 
  Corticosteroids (any) 9.3%  -3.5 (-8.2, 1.3) -3.4 (-8.2, 1.3) -0.5 (-1.1, 0.1)** -0.6 (-1.1, 0.0)** 
  Bisphosphonates 3.6%  -20.8 (-28.1, -13.5)* -20.2 (-27.6, -12.9)* -1.6 (-2.5, -0.7)* -1.8 (-2.7, -0.9)* 
  General Health       
  Health: good/excellent 85.9%  0.0 (-4.0, 4.0) 0.3 (-3.7, 4.3) 0.6 (0.1, 1.1)* 0.5 (0.0, 1.0)* 
  Neuromuscular       
  Gait speed (m/s) 1.2 ± 0.2 0.2 -0.2 (-1.7, 1.3) 0.1 (-1.4, 1.6) 0.4 (0.2, 0.6)* 0.4 (0.2, 0.6)* 
  Chair stands (s) 11.6 ± 3.4 3.4 0.2 (-1.3, 1.7) -0.1 (-1.6, 1.5) -0.3 (-0.5, -0.1)* -0.2 (-0.4, -0.1)* 
  Stands with arms 9.0%  -1.1 (-6.0, 3.8) -2.1 (-7.0, 2.8) -0.9 (-1.5, -0.3)* -0.7 (-1.3, -0.1)* 
  Grip strength (kg) 37.5 ± 7.7 7.7 -0.5 (-2.0, 1.0) -0.8 (-2.3, 0.7) 0.3 (0.1, 0.5)* 0.3 (0.1, 0.5)* 
+For continuous variables the units approximate 1 SD; for dichotomous variables, the referent group does not have the characteristic.   
P≤0.05* 
0.05<P≤0.1** 
++Effect of age alone, +++Effect of weight alone 
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Table 3-2 Percent difference in trabecular and cortical vBMD of the tibia per unit change in potential correlates for age and age and weight adjusted models 
Percent difference in vBMD per unit change (95% CI) Variable              Mean ± SD or  
Prevalence 
Unit+ 
Age Adjusted Trabecular 
vBMD 
Age and Weight Adjusted 
Trabecular vBMD 
Age Adjusted Cortical 
vBMD 
Age and Weight 
Adjusted Cortical 
vBMD 
   Demographics       
   Age (years) 77.2 ± 5.1 5.1 -1.8 (-2.8, -0.8) ++,* -1.3 (-2.4, -0.3) -0.4 (-0.6, -0.2) ++,* -0.5 (-0.7, -0.3)* 
   Race       
   Caucasian  97.9%  _ _ _ _ 
   African-American  1.4%  -7.0 (-15.9, 2.0) -6.3 (-15.3, 2.7) 0.3 (-1.3, 1.9) 0.2 (-1.4, 1.7) 
   Asian  0.2%  -15.0 (-39.4, 9.5) - 12.1 (-36.6, 12.3) 2.8 (-1.4, 7.0) 2.3 (-1.9, 6.5) 
   Hispanic  0.3%  -7.1 (-24.4, 10.3) -7.7 (-24.9, 9.6) 0.5 (-3.5, 2.5) -0.4 (-3.3, 2.6) 
   Other 0.2%  7.6 (-16.8, 32.1) 7.5 (-16.9, 31.8) 4.4 (0.2, 8.6)* 4.5 (0.3, 8.7)* 
   >High School Education 61.9%  2.7 (0.5, 4.7)* 2.7 (0.6, 4.8)* 0.5 (0.1, 0.8)* 0.6 (0.3, 1.0)* 
    Site 
    Monongahela Valley, PA 
 
53.9% 
  
-0.6 (-1.5, 2.6) 
 
-0.7 (-1.4, 2.7) 
 
-0.9 (-1.2, -0.5)* 
 
-0.9 (-1.2, -0.5)* 
   Anthropometry       
   Weight (kg) 83.9 ± 13.5 13.5 1.7 (0.6, 2.8) +++,* 1.7 (0.6, 2.8)* -0.3 (-0.5, -0.1) +++,* -0.3 (-0.5, -0.1)* 
   Height (cm) 173.0 ± 6.9 6.9 -0.2 (-1.3, 0.8) -1.3 (-2.4, -0.1)* 0.0 (-0.6, 0.2 ) 0.2 (0.0, 0.4)* 
   Lifestyle       
   Smoking 
   Never 
   Past 
   Current 
 
36.2% 
60.9% 
2.9% 
  
_ 
-3.0 (-5.2, -0.9)* 
-5.6 (-11.9, 0.4) ** 
 
_ 
-3.4 (-5.5, -1.2)* 
-5.7 (-11.8, 0.4)** 
 
_ 
-0.5 (-0.9, -0.1)* 
-0.6 (-1.6, 0.5) 
 
_ 
-0.5 (-0.8, -0.1)* 
-0.6 (-1.7, 0.4) 
   Caffeine intake (mg/day) 261.4  ± 259.3 259.3 -1.1 (-2.2, -0.1)* -1.2 (-2.2, -0.2)* -0.2 (-0.3, 0.0)** -0.2 (-0.3, 0.0)** 
   Alcohol (drinks/week)  3.7 ± 6.8 6.8 -0.4 (-1.4, 0.6) -0.6 (-1.6, 0.5) -0.2 (-0.3, 0.0)** -0.1 (-0.3, 0.0) 
   Physical activity (PASE) 141.4 ± 65.9 65.9 0.7 (-0.4, 1.7) 0.9 (-0.2, 1.9) 0.1 (-0.1, 0.3) 0.1 (-0.1, 0.3) 
   Walk for exercise (hrs/d) 1.8  ± 0.8 0.8 -0.4 (-1.5, 0.7) -0.3 (-1.4, 0.8) -0.01 (-0.2, 0.1) -0.1 (-0.3, 0.1) 
   Supplemental calcium  intake (mg/d) 278.3 ± 389.6 389.6 -0.0 (-1.0, 1.0) 0.1 (-0.9, 1.2) 0.3 (0.1, 0.5)* 0.3 (0.1, 0.5)* 
   Total calcium (mg/d) 1126.7  ± 564.9 564.9 1.1 (0.1, 2.1)* 1.2 (0.1, 2.3)* 0.3 (0.1, 0.5)* 0.3 (0.1, 0.5)* 
   Daily vitamin intake (IU/d) 172.8 ± 123.2 123.2 0.9 (-0.1, 1.9)** 0.9 (-0.1, 1.9)** -0.0 (-0.2, 0.2) -0.0 (-0.2, 0.2) 
   Medical History       
    Non-trauma fracture since age 50 15.3%  -8.2 (-11.0, -5.3)* -8.2 (-11.0, -5.4)* -0.9 (-1.4, -0.4)* -0.9 (-1.4, -0.4)* 
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    No diabetes  80.9%  - - - - 
    Diabetes and non-TZD use 
    Diabetes and TZD use 
15.8% 
3.3% 
 1.4 (-1.5, 4.2) 
9.2 (3.4, 15.0)* 
0.8 (-2.1, 3.6) 
7.9 (2.1, 13.8)* 
-3.8 (-0.8, 0.2) 
-0.6 (-1.1, 0.9) 
-2.3 (0.2, -0.6) 
0.2 (-0.8, 1.2) 
    Hypertension 52.8%  2.7 (0.6, 4.7)* 2.4 (0.2, 4.3)* 0.1 (-0.2, 0.5) 0.2 (-0.2, 0.6) 
    MI 17.1%  0.2 (-2.5, 2.9) 0.3 (-2.5, 3.0) -0.4 (-0.9, 0.1)** -0.4 (-0.9, 0.1)** 
    Stroke 6.9%  -0.3 (-4.4, 3.7) -0.5 (-4.6, 3.5) 0.2 (-0.5, 0.9) 0.3 (-0.4, 1.0) 
    Cancer 30.3%  0.3 (-0.2, 2.5) 0.4 (-0.5, 2.3) 0.1 (-0.3, 0.5) 0.1 (-0.3, 0.5) 
    Osteoporosis  3.5%  -14.0 (-19.5, -8.5)* -13.5 (-19.0, -8.0)* -2.0 (-3.0, -1.1)* -2.3 (-3.2, -1.4) 
    Rheumatoid Arthritis  6.1%  4.1 (-0.2, 8.4)** 3.7 (-0.6, 8.0)** -0.2 (-0.9, 0.6) -0.1 (-0.8, 0.7) 
    Osteoarthritis  22.5%  1.7 (-0.8, 4.1) 1.7 (-0.8, 4.1) -0.1 (-0.5, 0.4) -0.1 (-0.5, 0.4) 
    Hyperthyroid 2.5%  1.7 (-5.8, 8.6) 1.7 (-5.2, 8.5) 0.5 (-0.7, 1.7) 0.5 (-0.7, 1.7) 
    Hypothyroid  6.4%  -1.6 (-5.8, 2.5) -1.5 (-5.7, 2.6) 0.3 (-0.4, 1.1) 0.3 (-0.4, 1.0) 
    COPD 10.1%  -2.1 (-5.5, 1.3) -2.2 (-5.6, 1.2) -0.4 (-0.9, 0.2)** -0.4 (-0.9, 0.2)** 
    Parkinson’s  1.1%  -5.2 (-14.9, 4.4) -5.1 (-14.7, 4.5) 0.6 (-1.1, 2.2) 0.5 (-1.1, 2.2) 
    Gastrectomy  5.5%  -4.6 (-9.1, -0.2)* -4.6 (-9.1, -0.2)* -0.2 (-0.9, 0.6) -0.2 (-1.0, 0.6) 
     Kidney stones  13.3%  -2.7 (-5.7, 0.3)** -2.8 (-5.8, 0.2)** -0.0 (-0.6, 0.5) -0.0 (-0.5, 0.5) 
    Medications        
    Androgens 0.6%  11.2 (-1.9, 24.3)** 10.0 (-3.1, 23.1) 2.3 (0.1, 4.6)* 2.6 (0.3, 4.8)* 
    Testosterone injections 0.5%  8.0 (-6.2, 22.1) 7.0 (-7.1, 21.1) 0.6 (-1.8, 3.1) 0.8 (-1.6, 3.3) 
    Anti-androgen use 0.5%  -28.7 (-44.1, -13.3)* -28.6 (-44.0, -13.3)* -3.2 (-5.8, -0.5)* -3.2 (-5.8, -0.5)* 
    Cox-II inhibitor use  2.0%  -4.0 (-11.4, 3.4) -4.0 (-11.4, 3.4) -0.4 (-1.7, 0.8) -0.5 (-1.7, 0.8) 
    NSAID use  16.2%  0.8 (-2.0, 3.6) 0.4 (-2.4, 3.2) -0.3 (-0.7, 0.2) -0.2 (-0.7, 0.3) 
    Thiazide diuretic use  19.0%  2.6 (-0.1,5.2)** 2.1 (-0.5, 4.8)** 0.3 (-0.1, 0.8)** 0.4 (-0.1, 0.9)** 
    Non-thiazide diuretic use 11.8%  1.4 (-1.8, 4.6) 0.8 (-2.5, 4.0) -0.5 (-1.0, 0.1) -0.4 (-0.9, 0.2) 
    Loop diuretics use 7.5%  0.4 (-3.6, 4.4) -0.4 (-4.5, 3.6) -0.8 (-1.5, -0.2)* -0.7 (-1.4, -0.0)* 
    Statins 45.2%  -0.7 (-2.7, 1.4) -0.8 (-2.9, 1.3) -0.2 (-0.5, 0.2) -0.2 (-0.5, 0.2) 
    Nitrates  6.5%  0.3 (-3.9, 4.5) 0.2 (-3.9, 4.4) -0.1 ( -0.8, 0.7) -0.1 (-0.8, 0.7) 
    Beta blockers 33.3%  0.3 (-1.9, 2.4) -0.1 (-2.2, 2.1) -0.0 (-0.4,0.3) 0.0 (-0.4, 0.4) 
    Anti-convulsants  3.4%  -1.2 (-6.7, 4.4) -1.1 (-6.7, 4.4) -0.1 (-1.0, 0.9) -0.1 (-1.0, 0.9) 
    SSRI use 4.3%  3.5 (-1.6, 8.6) 3.2 (-1.9, 8.3) 0.3 (-0.6, 1.2) 0.4 (-0.5, 1.3) 
    Tricyclic antidepressants  1.1%  -1.8 (-12.2, 8.7) -2.5 (-12.9, 8.0) 1.2 (-0.6, 3.0) 1.3 (-0.5, 3.1) 
    Thyroid hormone use 8.4%  -0.8 (-4.5, 2.9) -0.8 (-4.7, 2.9) 0.4 (-0.3, 1.0) 0.3 (-0.3, 1.0) 
    Corticosteroid (any) use 9.3%  -2.4 (-5.9, 1.1) -2.3 (-5.8, 1.2) -0.3 (-0.9, 0.3) -0.3 (-0.9, 0.3) 
Table 3-2 continued. 
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    Bisphosphonates  3.6%  -15.6 (-20.9, -10.2)* -14.9 (-20.3, -9.5)* -1.3 (-2.3, -0.4)* -1.5 (-2.5, -0.6)* 
    General Health       
    Health: good/excellent  85.9%  2.9 (-0.0, 5.9)** 3.3 (0.4, 6.3)* 0.9 (0.4, 1.5)* 0.9 (0.4, 1.4)* 
    Neuromuscular       
    Gait speed (m/s) 1.2 ± 0.2 0.2 0.5 (-0.6, 1.6) 0.8 (-0.3, 2.0) 0.4 (0.8, 0.6)* 0.3 (0.1, 0.5)* 
    Chair stands (s) 11.6 ± 3.4 3.4 -0.2 (-1.2, 1.0) -0.5 (-1.6, 1.0) -0.3 (-0.5, -0.1)* -0.3 (-0.5, -0.1)* 
    Stands with arms 9.0%  -5.8 (-9.5, -2.1)* -6.9 (-10.6, -3.8)* -0.9 (-1.5, -0.3)* -0.8 (-1.4, -0.1)* 
    Grip strength (kg) 37.5 ± 7.7 7.7 -0.2 (-1.4, 0.9) -0.5 (-1.7, 0.6) 0.2 (-0.0, 0.4)** 0.2 (0.0, 4.3)* 
+For continuous variables the units approximate 1 SD; for dichotomous variables, the referent group does not have the characteristic.   
P≤0.05* 
   0.05<P≤0.1** 
   ++Effect of age alone. 
   +++Effect of weight alone  
Table 3-2 continued.
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Table 3-3 Percent difference in vBMD per unit change of each correlate using the backward elimination procedure for multiple linear regression models 
Percent change in vBMD per unit change (95%CI) 
Radius                                      Tibia Radius                                 Tibia 
 
Variables  
 
Unit 
Trabecular 
vBMD1 
Trabecular 
vBMD2 
Cortical vBMD3 Cortical 
vBMD4 
N  1058 1065 1048 990 
Demographics 
Age (years)  
 
5.1 
 
-0.6 (-1.9, 0.8) 
 
-1.2 (-2.3, -0.1) 
 
-0.4 (-0.6,-0.2) 
 
-0.4 (-0.6, -0.2) 
>High school education   - 3.0 (0.9,5.2) - - 
Site (Monongahela Valley, PA)  - - - -0.8 (-1.2, -0.4) 
Anthropometrics  
Weight (kg) 
 
13.5 
 
- 
 
2.3 (1.1, 3.6) 
- 
-0.5 (-0.7,-0.3) 
 
-0.3 (-0.5, -0.1) 
Height (m) 
Lifestyle  
6.9 - -1.6 (-2.8, -0.4) - - 
Caffeine intake (mg/d) 259.3 - -1.2 (-2.2, -0.2) -0.2 (-0.4, -0.1) -0.2 (-0.4, -0.1) 
Total calcium (mg/d) 564.9 2.5 (1.1, 3.9) 1.5 (0.5, 2.6) 0.2 (0.1, 0.4) 0.2 (0.1, 0.4) 
Past smoker  - - -0.4 (-0.8, -0.1) - 
Medical History       
Non-Trauma fracture (any)  -7.2 (-11.1, -3.4) -7.6 (-10.5, -4.8) -0.8 (-1.3, -0.3) -0.8 (-1.4, -0.3) 
Hypertension  5.0 (2.2, 7.8) - 0.6 (0.2, 0.9) - 
Diabetes and TZD use  9.3 (1.5, 17.0) 8.0 (2.2, 13.7) - - 
RA   - 5.3 (0.9, 9.6) - - 
Medications      
Androgens  - - 3.0 (0.9, 5.0) 2.7 (0.4, 5.0) 
Anti-androgen  - -24.9 (-43.9, -5.9) - - 
Neuromuscular Function      
Grip strength (kg) 7.7 - - 0.3 (0.1, 0.5) - 
Chair stands (s) 3.4 - - - -0.3 (-0.5, -0.1) 
Stands with arms  - -7.2 (-11.0, -3.4) - - 
R2  0.04 0.10 0.09 0.08 
1 Total calcium intake (mg/d), non-trauma fracture (any), hypertension, and diabetes and TZD use were significant in the model. 
 2Age, weight, height, education, caffeine intake (mg/d), total calcium intake (mg/d), non-trauma fracture (any), diabetes and TZD use, RA, anti-androgens,  and stands      
with arms were significant in the model. 
3Age, weight (kg), caffeine intake (mg/d), total calcium intake (mg/d), past smoker, non-trauma fracture (any), hypertension, androgens, grip strength (kg) were 
significant in the model.  
4Age, weight (kg), site, caffeine intake (mg/d), total calcium intake (mg/d), non-trauma fracture (any), androgens, and time to complete 5 chair stands (s) were 
significant in the model.  
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4.1 ABSTRACT 
There are limited data on serum 25-hydroxyvitamin D [25(OH)D] and bone density and geometry in older men 
of African heritage. To better understand if there are racial differences in vitamin D status and indices of bone 
strength we determined the association of 25(OH)D with peripheral quantitative computed tomography 
(pQCT) parameters including trabecular and cortical volumetric bone mineral density (vBMD), bone mineral 
content (BMC), bone geometry, and polar and axial strength strain index (SSIp and SSIx) among  Caucasian 
(N=446) men living in the US and men of African (N=496) descent living in Tobago aged ≥65 years. Serum 
concentrations of total (D2 +D3) 25(OH)D were measured using liquid chromatography and tandem  mass 
spectrometry and categorized as using clinical categories defined as sufficient (≥ 30 ng/ml), insufficient (20-
<30 ng/ml) and deficient (<20 ng/ml).  Men of African descent had higher 25(OH)D concentrations than 
Caucasians (34.7 vs. 27.6 ng/ml, p<0.001). In Caucasians, increasing 25(OH)D was associated with greater 
cortical vBMD (p trend=0.042), total BMC (p trend=0.007), cortical  thickness (p trend=0.004), and SSIp (p 
trend=0.028) and SSIx (p trend =0.012) at the distal radius after adjusting for covariates including age, BMI, 
season of blood draw, and history of fracture. These associations were significant at the distal tibia, with the 
exception of cortical vBMD and SSI parameters. There was also greater total BMC among 25(OH)D sufficient 
versus deficient men at the distal radius and tibia. In contrast, in men of African descent, higher 25(OH)D 
levels were associated with lower total bone area (p trend=0.005) and SSIx (p trend=0.048). There was strong 
evidence that the association between 25OHD and pQCT parameters depended on race. Race modified the 
association between 25(OH)D and total BMC (p interaction=0.003), total bone area (p interaction=0.006), 
SSIp(p interaction=0.006), SSIx (p interaction=0.002), and  trabecular vBMD (p interaction=0.015) of the 
radius. In Caucasians, there was evidence of a threshold effect on tibial total BMC and cortical thickness at 19 
and 18 ng/ml of serum 25(OH)D, respectively. Beyond this 25(OH)D level, the effects of higher 25(OH)D 
levels on bone parameters appeared to be minimal. Prospective studies in diverse populations are needed to 
evaluate the association of 25(OH)D with trabecular and cortical bone loss in older men.  
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4.2 INTRODUCTION 
Serum 25-hydroxyvitamin D (25(OH)D) is an indicator of vitamin D nutritional status(1) and 
decreases with advancing age.(2-4)  The possible mechanisms for the age related loss in serum 
25 (OH)D include lower vitamin D intake(5), decreased vitamin D absorption(6), limited sun 
exposure(2) and decreased cutaneous synthesis of vitamin D.(7)   Low 25(OH)D levels have 
been linked to several comorbidities including Myocardial Infarction (MI), hypertension, 
osteoarthritis, and diabetes.(8-11)  Vitamin D deficiency can also have a profound impact on 
bone growth and bone mineralization  in young adults and on bone loss in older adults.(12)   
Low bone mineral density(BMD) and osteoporosis is an increasing clinical and public 
health problem among older men.(13-15)  Positive (16-24) and null(20;25;26) associations 
between serum 25(OH)D concentrations and areal bone mineral density (aBMD) have been 
reported in men.  However, limitations of past studies include small sample sizes, failure to 
adjust for important confounders, reliance on dual X-ray absorptiometry (DXA) assessments of 
areal BMD(27), and the use of unreliable radioimmunoassay methods to measure serum 
25(OH)D levels. Binkley et al. found markedly different serum 25(OH)D values after comparing 
radioimmunoassay (RIA) and competitive binding protein assays to high performance liquid 
chromatography (HPLC).(28)  The use of RIA or competitive binding protein assays have been 
shown to overestimate 25(OH)D levels and have poorer reliability compared to HPLC and  
liquid chromatography tandem mass spectrometry (LC-MS/MS) methods.(29;30) Moreover, 
most studies have focused on Caucasian men; there are limited data on serum 25(OH)D 
concentrations and bone density and geometry in men of African ancestry residing in the 
Caribbean.   
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 In this current study, we determined the associations between serum 25(OH)D levels 
measured using LC-MS/MS and bone mineral content (BMC), trabecular and cortical  
volumetric BMD, and bone structural geometry at the radius and tibia in men of Caucasian and 
African descent.   
4.3 METHODS 
4.3.1 Study population 
The Osteoporotic Fractures in Men Study (MrOS) initially recruited 5995 men ages 65 and older 
from March 2000 through April 2002 as previously described.(31;32)  Men with a history of 
bilateral hip replacement and men who were unable to walk without the assistance of another 
person were excluded from MrOS.  5229 men (95.5% of survivors) completed some portion of 
the second visit between March 21st, 2005 and May 3rd, 2006.  For the current 25(OH)D sub-
study, the Pittsburgh MrOS site was included for this analysis. Caucasian subjects (N=446) that 
had peripheral quantitative computed tomography (pQCT) measurements at visit 2 and visit 3 
(March 2007-March 2009), were selected to have their serum assayed for 25(OH)D. However, 
the analysis was limited to pQCT measurements at visit 2. 
Between 1997 and 2003, 3,170 men aged 40 years or older were recruited for the 
population based prostate cancer screening study on the Island of Tobago.(33)  Eligible men had 
to be ambulatory, non-institutionalized and not terminally ill.   Between 2004 and 2007, 2482 
men (70% of survivors) completed a second clinic visit.(34)  There were 618 Afro-Caribbean 
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men aged ≥65 years (with all 4 grandparents of African ancestry).  A random sample of 496 of 
these men was chosen for 25(OH)D and pQCT measurements.  The Institutional Review Board 
(IRB) for the University of Pittsburgh and the Tobago Division of Health and Social Services 
approved the study protocol and written informed consent was obtained from all participants.      
4.3.2 Measurement of 25(OH)D 
Measures for 25(OH)D2 (derived from ergocalciferol) and 25(OH)D3 (derived from 
cholecalciferol) in both cohorts were performed simultaneously at the Mayo Clinic by 
conventional LC-MS/MS as previously described in serum collected after an overnight fast and 
frozen until assay.(35)  The minimum detectable limit for 25(OH)D2 was 4 ng/mL and for 
25(OH)D3 was 2 ng/mL.  The number of men with detectable 25(OH)D2 was 193 (20.5%), 
similar to a prior report.(17)  Total 25(OH)D was  quantified as the sum of 25(OH)D2 and 
25(OH)D3.  Reliability was assessed by measuring 46 duplicate 25(OH)D3 samples from the 
Caucasian population and the coefficient of variation (CV) was 5.8% for total 25(OH)D and 
3.9% for 25(OH)D3. 
4.3.3 Peripheral QCT Measurements  
QCT examinations for visit 2 at both sites were performed on the Stratec XCT scanner series 
2000.  Trabecular bone properties were measured by taking an ultra distal slice at 4% of the 
length of the radius and tibia.  Variables measured at this site included total bone area (mm2), 
total BMC (mg/mm), trabecular vBMD (mg/cm3), and the polar (SSIp) and axial (SSIx) strength 
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strain index (mm3). Cortical bone properties were measured at a 33% slice of the radius and tibia.  
Measurements at this site included total bone area (mm2), total BMC (mg/mm), cortical vBMD 
(mg/cm3), cortical thickness (mm), and SSIp and SSIx (mm4).  The strength strain indices denote 
the density-weighted polar or axial section moduli and reflect the torsional and bending rigidity 
of the long bone shaft (mm3).(36)  SSI= =∫d2A*(vBMDvox/vBMDmax)/dmax, where 
vBMDvox=bone density of a voxel and vBMDmax=1200 mg/cm3, maximal bone density, and 
dmax=maximum distance of a voxel from the center of mass.(37)  A scoutview (an anatomic 
reference line for the relative location of subsequent scans) was obtained prior to the pQCT scan 
at the tibia and radius.  High quality assessment of bone mineral properties by pQCT was assured 
by minimizing participant movement.  A quality assurance (QA) phantom scan was scanned 
daily and used to monitor the stability of each pQCT scanner.  QA scan checks that the density 
(attenuation) of the phantom does not change by more than +/- 0.5% which would be logged as a 
failure.  No failures were noted for each scanning center.  A cross-calibration check was also 
performed between the centers. The European Forearm Phantom (EFP) was scanned 3 times at 
each site at 200, 100 and 50 mg/cc, respectively.  The same EFP was scanned at both centers and 
the densities compared to the densities certified for the EFP.  The densities for all sections of the 
EFP were accurately determined by each scanning center within the machine precision (3-5 
mg/cc).  No corrections/adjustments were applied to the data from each of the scanning centers 
to account for any machine bias (none existed).  Voxel size was 0.5 mm and the scan speed was 
25 mm/s. Coefficients of variation (CV) were determined for pQCT scans by replicating 
measurements on 15 subjects (CV ≤ 2.1%).(38) 
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4.3.4 Potential Confounders  
Questionnaires and clinical evaluations were administered by trained clinical staff to obtain 
demographic, anthropometric, medical and lifestyle information from the participants.(39)  
Demographic, lifestyle, and medical characteristics were obtained entirely through self-report 
with the exception of diabetes.  Men were classified as having diabetes, if they self-reported 
diabetes, took insulin, or hypoglycemic medications (baseline or visit 2), or had glucose levels 
≥126 mg/dl after a minimum of an 8 hour fast (at baseline). 
All variables in MrOS with the exception of education (attended college versus never 
attended college), history of fracture, and alcohol intake (drinks/week), dietary calcium 
(mg/day), supplemental calcium (yes or no), and health status (Excellent/good vs. fair/poor/very 
poor) were obtained at visit 2.    
Season of blood draw was categorized winter: January-March; spring: April-June; 
summer: July-September; fall: October-December. A calibrated balance beam scale was used to 
measure weight in kilograms (kg).  Participants had to wear indoor clothing and remove their 
shoes when their weight was being measured.  Height was measured in centimeters (cm) using a 
Harpenden Stadiometer (Dyfed, UK) or wall mounted height board.  BMI was calculated using 
weight (kg)/height/(m2).  Other lifestyle factors included self-report of current smoking (yes or 
no), caffeine intake (mg/day), and average time walking per day in previous 7 days (≤1 hour, >1 
hour).  Dietary information on calcium and caffeine intake in Mr. OS was obtained using the 
modified Block Food Frequency.(40)  Caffeine intake was assessed for Tobago men by assuming 
that one cup of caffeinated coffee, tea or soda contained 95, 55 and 45mg of caffeine, 
respectively.  Dietary calcium intake in this population was determined by frequency of selected 
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food items including fish, bone chewing, green leafy vegetables, beans, milk, cheese, and cheese 
dishes that contain high dietary calcium and are frequently consumed in the local diet.(41)  
Subjects were asked to report if a doctor or health care provider informed them they had certain 
medical conditions including history of fracture, hypertension, MI, osteoporosis, osteoarthritis 
and rheumatoid arthritis (RA).   
4.3.5 Statistical Analysis 
All statistical analyses were performed using the Statistical Analysis System (SAS, version 9.1; 
SAS Institute, Cary, NC). Clinical cutoffs defined 25(OH)D “deficiency” as <20 ng/ml, 
“insufficiency” as 20-<30 ng/ml, and “sufficiency” as ≥30 ng/ml based on previous reports.(1)  
Chi-square tests for categorical variables and Analysis of Variance (ANOVA) for continuous 
variables were performed to test if baseline characteristics differed by 25(OH)D status.  Fisher’s 
exact test was used when the expected frequency was less than 5.  The Kruskal-Wallis test was 
used if a continuous variable was not normally distributed.  Race specific linear regression 
analysis was used to calculate least square means and examine associations between 25(OH)D 
and pQCT parameters.  A Bonferroni correction was used to adjust for pairwise comparisons 
between 25(OH)D groups and pQCT parameters.  Factors consistently associated with different 
bone parameters or those related to 25(OH)D level at p<0.05 were considered for inclusion in 
multivariable models.  Interactions between race and vitamin D cutoffs were assessed to evaluate 
if the association between 25(OH)D and pQCT parameters differed by race.  A test of linear 
trend across 25(OH)D clinical cutoffs was also performed based on the ordinal value for each 
category. To further explore these relationships, we performed spline analysis to test for possible 
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thresholds and linearity for all bone parameters.  Restricted cubic spline linear regression was 
used with knots at the 5th, 25th, 75th and a reference group at the 95th percentile was set to 
create the spline plot.  Predicted values from the regression were plotted against the 25(OH)D 
values.  Threshold effects were evaluated by identifying potential inflection points on the spline 
and performing a test of equality to determine if the slopes above and below the cut point were 
equal.  If more than one cutoff was identified (p<0.05) we chose the 25(OH)D value with the 
lowest p-value as the threshold.  Spline plots were displayed if 25(OH)D thresholds were found.  
An additional analysis using 25(OH)D tertiles (based on the distribution of the entire population) 
was performed and the results were similar (not shown to avoid redundancy) to the analysis with 
clinical cutoffs.  The purpose of this analysis was descriptive; therefore multiple outcomes are 
presented without adjusting for multiple comparisons.    
4.4 RESULTS 
Men of African descent had greater serum 25(OH)D (34.7 vs. 27.6 ng/ml, p<0.001) than 
Caucasians (Table 4-1).  Caucasians were older and had greater BMI, caffeine intake, and dietary 
calcium intake than men of African descent.  Caucasian men were also significantly more likely 
to have a college education, take calcium supplements, report good/excellent health, history of a 
fracture, and hypertension.  Men of African descent had a greater prevalence of diabetes than 
Caucasians.  
Table 4-2 shows baseline characteristics by cutpoints of 25(OH)D. Caucasian men who 
were 25(OH)D sufficient had lower BMI, higher probability of taking calcium supplements, less 
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likely to have RA and MI, and have their blood drawn in the summer than  deficient men.  
Vitamin D sufficient men of African descent were less likely to have a history of a fracture than 
deficient men. 
4.4.1 Association of 25(OH)D and pQCT parameters at the radius  
At the distal radius, Caucasian men with sufficient 25(OH)D had greater total BMC (132.4 vs. 
125.7 mg/mm, p=0.044), cortical thickness (3.32 vs. 3.11 mm, p=0.016) than deficient men 
(Table 4-3).  Positive linear trends were observed for 25(OH)D level and cortical vBMD 
(p=0.042), total BMC content (p trend=0.007), cortical thickness (p trend=0.003) and  SSIp (p 
trend=0.028) and SSIx (p trend=0.012).   In men of African descent, 25(OH)D was negatively 
associated with total bone area  (p for trend=0.005) and there was a borderline significant inverse 
association for SSIp (p for trend=0.060) and SSIx (p for trend=0.048).  At the ultra distal radius, 
there was no association between 25(OH)D and any skeletal parameters among men of either 
Caucasian or African descent. 
4.4.2 Association between 25(OH)D status and pQCT parameters at the tibia 
Caucasians with sufficient 25(OH)D had greater total BMC (396.4 vs. 378.4 mm/mg, p=0.037) 
and cortical thickness (5.54 vs. 5.33 mm, p=0.017) than deficient and insufficient men (at distal 
radius), respectively (Table 4-3). There were positive linear trends at this skeletal site for total 
BMC (p=0.012) and cortical thickness (p for trend=0.009) in Caucasians.  None of the tibial 
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measures were associated with 25(OH)D in men of African descent. Also, no significant 
associations were found at the ultra distal region for men of either race.  
4.4.3 Effect of race on the association between 25(OH)D status and pQCT parameter?
Significant interactions were observed between race and 25(OH)D primarily at the distal 
radius. Race modified the association between 25(OH)D levels and total BMC (p for 
interaction=0.003), total bone area (p for interaction=0.006), SSIp (p for interaction=0.005) and 
SSIx (p for interaction=0.002).  The associations between 25(OH)D and total BMC, total bone 
area, and SSIp and SSIx were positive for Caucasians and  null or negative for men of African 
descent leading to the significant interaction.  Race also significantly (p=0.015) modified the 
association between 25(OH)D and trabecular vBMD at the ultra distal radius.  Caucasians had 
lower radial trabecular vBMD in the sufficient (181.6 mg/cm3) and insufficient (182.5 mg/cm3) 
groups when compared to the deficient (194.0 mg/cm3) group, p for trend=0.118.  On the other 
hand men of African descent had greater trabecular vBMD with increasing 25(OH)D, but the 
trend was not significant.   
4.4.4 Restricted Cubic Spline Analysis 
There was evidence of a threshold effect on tibial total BMC (p for test of non-equal 
slopes=0.026) at 19 ng/ml of serum 25(OH)D among Caucasians (Figure 4-1).  For tibial cortical 
thickness a threshold (p for test of non-equal slopes=0.011) was also identified for serum 
25(OH)D at 18 ng/ml (Figure 4-2).  These thresholds identified the approximate 25(OH)D levels 
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at which there is greater tibial total BMC and cortical thickness.  In men of African descent, we 
observed no significant thresholds for any of the bone parameters. 
4.5 DISCUSSION 
In two cohorts of community dwelling men, we found that the association between serum 
25(OH)D levels and pQCT measures differed by race. Among Caucasians residing in the US, 
there were significant associations between 25(OH)D and  BMC, cortical thickness, SSIp and 
SSIx .  However, in men of African descent residing in the Caribbean, the associations for 
25(OH)D and pQCT parameters were primarily null.  
Interactions found at the distal (BMC, area, SSIp, and SSI) and the ultra distal 
(trabecular vBMD) radius suggested that race modified the association between 25(OH)D and 
these skeletal parameters.  In the Caucasian cohort, the associations were primarily positive 
between 25(OH)D and total BMC, total area, SSIp and SSIx at the distal radius, while in the 
African descent cohort these associations were either null or negative.  However, for trabecular 
vBMD, Caucasian men with 25(OH)D sufficiency had lower vBMD than deficient men.  On the 
other hand, men of African descent who were sufficient for 25(OH)D had greater trabecular 
vBMD than those who were deficient.   A previous study failed to find a significant race by 
25(OH)D interaction effect on hip, lumbar spine, and radial aBMD in a cohort of Caucasian, 
African American, and Hispanic men.(23) However, this cohort was significantly  younger 
(mean age 48 years) and the negative association between 25(OH)D and aBMD in African 
Americans was smaller than in our study.(23)   
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The mean serum concentrations of 25(OH)D were substantially higher in the African 
ancestry compared with Caucasian men in our study.  Several explanatory factors for this 
observation may include the higher exposure to sunlight, lower BMI (vitamin D is a lipid soluble 
molecule), and lower smoking and alcohol consumption among the men of African descent.  
Serum levels of 25(OH)D are generally lower among blacks compared with Caucasian 
individuals in the US(4) African Americans typically have lower levels of serum 25(OH)D than 
Caucasians across all age groups and both genders due at least in part to differences in skin 
pigmentation and dietary vitamin D intake (4;42-45).  However, mean 25(OH)D concentrations 
in the African continent are relatively high, but vary considerably according to geography, 
climate, and other factors.(46)  There are limited data in other African ancestry populations, 
particularly in tropical climates where there is high sun exposure such as on the Caribbean island 
of Tobago where our subjects were recruited.
 
   Although several studies have examined the cross-sectional association between 
25(OH)D and different bone measures in men(16;18;19;21-23;47-49), most inadequately 
controlled for confounders, only included Caucasians, used unreliable assay methods, estimated 
aBMD instead of vBMD, and were unable to distinguish cortical and trabecular bone.  Direct 
comparison of our 25(OH)D concentrations with other studies is difficult because different cut 
points have been used to define deficiency/insufficiency, and values were derived using different 
assay methods. The serum 25(OH)D levels in this study (despite being relatively high in men of 
African descent) were lower than studies that have used RIA or protein binding assays (reported 
means ≥40 ng/ml), but compare well to HPLC and studies that have used LC-MS/MS.(28-30) 
Similar to our findings, the MINOS study found that 25(OH)D levels (measured with RIA) were 
positively associated with cortical thickness (p<0.05) and BMC (p<0.01) at the femoral neck in 
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older (ages 56-85) Caucasian men after adjusting for age, body weight, testosterone 
concentration, and season.(18) Similarly, the Rancho Bernardo study reported that 25(OH)D 
(measured with a competitive binding protein assay)  was positively associated with aBMD at 
the hip (p=0.01) and spine (p=0.001) among 414 Caucasian men (mean age 74 years) in 
multivariable models.(19)  Conversely, another study that included 372 men aged 65-96, 
reported that 25(OH)D (measured with RIA) was not associated with cortical vBMD in 
Caucasian men.(48)   
Few past studies have found the association of serum 25(OH)D with skeletal 
parameters in ethnic minorities.(16;23)  The National Health and Nutritional Examination 
Survey (NHANES III) which included 13,432 participants of Caucasian, Mexican and African 
heritage found a positive association between race specific 25(OH)D (measured by RIA) 
quintiles and total hip aBMD in  men aged 50 years and older for all ethnic groups.  However, 
the mean difference in hip aBMD between the highest and lowest quintile was larger in 
Caucasians (0.040 g/cm2, p<0.001) than men of African descent (0.024 g/cm2, p=0.03) after 
adjustment for potential confounders.(16)  On the other hand, Hannan et al. found no association 
between 25(OH)D and hip, spine, and radial aBMD among 331 black men in Massachusetts.(23) 
We found no associations between 25(OH)D and vBMD in men of African descent.  However, 
men of African descent had lower bone area, SSIp and SSIx with greater 25(OH)D 
concentration.  There is no clear explanation for why men of African descent would have lower 
bone size and strength with higher 25(OH)D.  Intermittent and chronic PTH regimens have been 
shown to stimulate osteoblastic bone formation at the periosteal surface and postpone osteoblast 
apoptosis resulting in greater bone area and cortical thickness and thus bone strength(50;51)  
Also, men of African descent have also been shown to be resistant to the resorptive effects of 
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PTH on bone and markers of bone resorption.(52) Other potential factors identified that may be 
related to these disparate ethnic differences are the polymorphisms in the vitamin D receptor 
(VDR) gene.(53)  The absence of the BsmI restriction site and the FokI polymorphism for the 
VDR receptor occur at a higher frequency in whites than blacks and were found to be associated 
with lower aBMD.(54-56)      
The associations of serum 25(OH)D and bone parameters were only observed at the distal 
(cortical) bone regions of the radius and tibia.  Consistent with our findings, Lauretani et al. 
found that 25(OH)D was positively associated with tibial cortical vBMD, but not trabecular 
vBMD in women.(48) The mechanisms responsible for the differential associations of 25(OH)D 
with cortical versus trabecular bone are unclear.  PTH excess has been shown to have primarily 
catabolic effects on cortical bone and maintain or even have anabolic effects on trabecular 
bone.(57)  Several studies have shown that PTH administration and elevated serum PTH levels 
were associated with preserved trabecular bone structure.(58-62)  In cortical bone, excess levels 
of PTH can result in increased endocortical resorption, cortical thinning and cortical 
porosity.(63;64)   
Serum 25(OH)D thresholds were identified for total BMC and cortical thickness at the 
tibia in Caucasians.  The optimal serum 25(OH)D concentration needed to maintain adequate 
bone density and geometry has not been established.(65)  Optimal concentrations have been 
defined as those for which PTH levels plateau in the normal range.(66)  However, this definition 
has led to the reporting of a wide range of 25(OH)D thresholds: from 8 to 46 ng/ml.  A previous 
cross-sectional study based on aBMD levels found a threshold at 31 ng/ml with a target of 37 to 
41 ng/ml for 25(OH)D for men and women aged ≥20 years of Caucasian, Mexican and African 
American descent.(16)  Our results suggest a 25(OH)D threshold among older Caucasian men at 
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19 and 18 ng/ml for total BMC and cortical thickness at the tibia, respectively. The association of 
25(OH)D with tibial total BMC and tibial cortical thickness appears to be positive and linear at 
values less than the threshold and null above these values.  Recent cohort studies in older men 
and women found that hip fracture risk was reduced among participants with 25(OH)D levels 
>20 ng/ml.(65;67).   In addition, men with 25(OH)D levels below 20 ng/ml experienced greater 
hip aBMD loss while rates were similar at higher levels.(17)  All of this evidence suggests a 
lower 25(OH)D threshold may exist for bone density and geometry than previously recognized.  
Interestingly, 95% of the African ancestry men had 25(OH)D concentrations above these 
thresholds in Caucasians.  This may explain the absence of associations between 25(OH)D with 
bone measures among the African ancestry men in the current study.       
There are no known  reports on the prospective impact of baseline  pQCT measurements   
on fracture risk.  However, a recent report using the MrOS cohort found that the strongest 
predictor of non-vertebral fracture was SSIx (HR=2.2 per SD decrease).(68)  There was also a 
70% increase in risk of fracture per SD decrease in total BMC of the radius.  The difference 
between 25(OH)D sufficiency and deficiency (Caucasians) for total BMC and SSIx in our study 
was approximately 0.4 SDs.  Among the elderly, differences  of 0.5 SD in BMD can greatly 
increase the risk of an osteoporotic fracture.(69)     
This report had several potential limitations. Comparisons of these findings to other 
studies is limited primarily due to differences in 25(OH)D assay methods.  Also, the two cohorts 
in our study varied considerably.  Men of African descent had markedly lower calcium intake, 
caffeine intake, physical activity, education, and prevalence of fracture and MI, compared to 
Caucasians.  Therefore, we were unable to infer whether race modified the association between 
25(OH)D and skeletal parameters based on strictly biological differences, lifestyle disparities, or 
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a combination of both factors. Also, participants selected from the MrOS cohort may have been 
potentially healthier than other members of the cohort based on exclusion of subjects that were 
unable to participate in follow-up pQCT scans.  However, after comparing characteristics of 
selected MrOS subjects to those that were excluded they only differed significantly by age (76.9 
years vs. 78.0 years, respectively).  Finally, by having multiple outcomes some of findings may 
reach significance by chance alone.  However, our  study also has several notable strengths 
including the use of a LC-MS/MS assay to measure serum 25(OH)D, adjustment for many 
potential confounders, a large sample of men of African descent, and the use of pQCT to 
measure vBMD, geometry, indices of bone strength, and distinguish cortical and trabecular bone. 
In summary, men of Caucasian and African descent differed in the association of serum 
25(OH)D levels to several skeletal parameters.   Levels of serum 25(OH)D were more likely to 
be associated with bone measures in Caucasians than men of African descent.  Thresholds for 
25(OH)D were identified for Caucasians at approximately 20 ng/ml indicating that above this 
level there is minimal relationship with bone measures.  The association between 25(OH)D and 
bone measures was more evident at the regions that primarily consist of cortical bone.  
Prospective studies that analyze the association of serum 25(OH)D with trabecular and cortical 
bone loss in men of different ethnicities are needed. 
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Figure 4-2 Restricted Cubic Spline Plot for Tibial Cortical Thickness by Serum 25(OH)D in 
Caucasians
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Table 4-1 Baseline characteristics by race  
 Caucasians 
(N=446) 
African Descent 
(N=496) 
P-value 
Serum 25(OH)D level, mean (SD), ng/ml 27.6  ± 8.3 34.7 ± 9.7 <0.001 
Age, mean (SD),yrs 76.9 ± 4.9 71.6 ± 5.9 <0.001 
BMI, mean (SD), kg/m2  28.5 ± 4.2 27.2 ± 9.1 0.009 
Season of blood draw, % 
  Winter 
  Spring 
  Summer  
   Fall 
 
24.2 
26.7 
24.9 
24.2 
 
31.6 
20.0 
20.4 
28.0 
0.006 
Attended college, % 46.9 3.8 <0.001 
Average walk time per day,% 
  ≤1 hour 
  >1 hour  
 
45.7 
53.3 
 
92.7 
7.3 
 
Caffeine intake, median (IQR), mg/day 184.0 (0.0-408.0) 100.0 (45.0-150.0) <0.001 
Alcohol, median (IQR), drinks/week 0.5 (0.0-6.0) 0.0 (0.0-1.0) <0.001 
Smoking currently,% 3.6 6.1 0.080 
Dietary calcium intake, mean (SD), mg/day 793.5 ± 356 439.0 ± 209.8 <0.001 
Supplemental calcium, % 64.6 28.8 <0.001 
Health good or excellent, % 89.2 82.0 0.002 
History of any fracture, % 54.7 13.0 <0.001 
Diabetes, % 19.7 34.1 <0.001 
Hypertension, % 52.9 46.2 0.041 
Myocardial Infarction, % 16.1 1.4 <0.001 
Osteoporosis, % 3.6 3.1 0.716 
Osteoarthritis, % 26.7 5.6 <0.001 
Rheumatoid arthritis, % 6.7 3.7 0.040 
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Table 4-2 Baseline characteristics by clinical cutoffs of total serum 25(OH)D (ng/ml) 
Caucasians African Descent  
Deficient 
(<20) 
N=70 
Insufficient 
(20-<30) N=214 
Sufficient (≥30) 
N=162 
p-
value 
Deficient (<20) 
N=22 
Insufficient (20-
<30) N=122 
Sufficient (≥30) 
N=352 
p-
value 
Age, mean (SD),yrs 77.5 ± 5.1 76.9 ± 4.8 76.7 ± 4.8 0.581 72.8 ± 7.5 72.1 ± 6.4 71.4 ± 5.7 0.339 
BMI, mean (SD), kg/m2  29.0 ± 4.6 28.8 ± 4.1 27.8 ± 4.0 0.022 27.1 ± 4.5 28.3 ± 4.9 26.9 ± 10.3 0.347 
Season of blood draw, % 
  Winter 
  Spring 
  Summer  
   Fall 
 
38.6 
21.4 
14.3 
25.7 
 
25.2 
31.3 
23.4 
20.1 
 
16.7 
22.8 
31.5 
29.0 
0.001  
40.9 
22.7 
13.7 
22.7 
 
36.1 
18.9 
22.1 
22.9 
29.5 
20.2 
20.2 
30.1 
0.599 
Attended college, % 48.6 50.9 40.7 0.139 4.6 5.7 3.1 0.346 
Average walk time per day,% 
  ≤1 hour 
  >1 hour 
 
55.7 
44.3 
 
43.9 
56.1 
 
43.8 
56.2 
0.606  
95.5 
4.5 
 
82.0 
18.0 
 
85.0 
15.0 
0.603 
Caffeine intake, median (IQR), mg/day 272.0 (136.0-408.0) 192.0 (0.0-368.0) 140.0 (0.0-408.0) 0.164 75.0 (45.0-150.0) 100.0 (45.0-150.0) 100.0 (45.0-150.0) 0.682 
Alcohol, median  (IQR), drinks/week 0.5 (0.0-4.0) 0.6 (0.0-6.0) 0.5 (0.0-6.0) 0.706 0.0 (0.0-1.0) 0.0 (0.0-1.0) 0.0 (0.0-1.0) 0.289 
Smoking currently,% 5.7 2.3 4.3 0.326 9.1 4.9 6.3 0.609 
Dietary calcium, mean (SD), mg/day 727.0  ± 333.5 792.6 ± 360.7 823.4 ± 357.3 0.167 389.2 ± 198.3 443.1 ± 201.2 440.7 ± 213.5 0.520 
Supplemental calcium, % 44.3 65.0 72.8 0.002 23.8 31.3 28.3 0.730 
Health good or excellent, % 84.3 89.7 90.7 0.330 81.8 82.0 82.1 0.999 
History of any fracture, % 55.7 51.4 58.6 0.371 27.3 8.4 13.7 0.042 
Diabetes, % 24.3 19.6 17.9 0.532 31.8 36.1 33.5 0.855 
Hypertension, % 61.4 51.9 50.6 0.290 47.3 42.2 47.3 0.525 
Myocardial Infarction, % 15.7 21.0 9.9 0.014 4.6 0.8 1.4 0.329 
Osteoporosis, % 4.3 4.2 2.5 0.619 4.6 3.3 2.9 0.892 
Osteoarthritis, % 27.1 25.7 27.8 0.899 18.2 4.2 5.3 0.051 
Rheumatoid arthritis, % 14.3 5.1 5.6 0.023 4.6 5.8 2.9 0.204 
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Table 4-3 The distribution of measures of density, geometry, and bone strength by clinical cutoffs for total serum 25(OH)D (ng/ml) 
 Caucasians  African Descent  
 Deficient 
(<20)  
N=70 
Mean (SE) 
Insufficient 
(20-<30) 
N=214 
Mean (SE) 
Sufficient 
(≥30) 
N=162 
Mean (SE) 
P for 
trend 
Deficient 
(<20)  
N=22 
Mean (SE) 
Insufficient 
(20-<30) 
N=122 
Mean (SE) 
Sufficient 
(≥30) 
N=352 
Mean (SE) 
p for 
trend 
P for interaction 
between race 
and serum 25 
(OH)D 
 Distal radius (33%)         
Cortical vBMD (mg/cm3) 1149.3 (6.7) 1151.6 (6.1) 1158.3 (6.3) 0.042 1200.7 (6.3) 1199.6 (2.8) 1203.9 (1.6) 0.229 0.359 
Total bone mineral content (mg/mm) 125.7 (3.6) 128.0 (3.3) 132.4 (3.4)* 0.007 149.4 (4.1) 147.2 (1.8) 144.5 (1.1) 0.107 0.003 
Cortical thickness (mm) 3.11 (0.10) 3.19 (0.09) 3.32 (0.09)* 0.003 3.52 (0.09) 3.52 (0.04) 3.54 (0.02) 0.670 0.054 
Total area (mm2) 143.2 (4.1) 143.4 (3.8) 145.9 (3.9) 0.291 161.6 (5.0) 155.7 (2.2) 150.5 (1.3) 0.005 0.006 
SSIp (mm3) 354.0 (14.4) 363.3 (13.3) 376.5 (13.7) 0.028 436.4 (18.2) 426.3 (8.1) 412.1 (4.7) 0.060 0.005 
SSIx (mm3) 193.5 (7.9) 200.0 (7.3) 207.8 (7.5) 0.012 243.2 (10.4) 239.9 (4.6) 230.4 (2.7) 0.048 0.002 
Ultra distal radius (4%)        
Trabecular vBMD (mg/cm3) 194.0 (9.0) 182.5 (8.3) 181.6 (8.5) 0.118 187.5 (11.9) 201.2 (5.3) 204.9 (3.0) 0.170 0.015 
Total bone mineral content (mg/mm) 126.1 (4.8) 122.6 (4.5) 127.9 (4.6) 0.310 139.7 (5.4) 142.1 (2.4) 140.6 (1.4) 0.792 0.480 
Total area (mm2) 361.9 (13.6) 362.4 (12.6) 371.8 (13.0) 0.244 349.3 (13.0) 354.3 (5.8) 344.6 (3.3) 0.217 0.109 
SSIp (mm3) 493.8 (27.0) 484.6 (25.0) 516.6 (25.8) 0.118 596.1 (30.2) 589.3 (13.4) 576.2 (7.7) 0.327 0.079 
SSIx (mm3)  267.9 (14.8) 258.6 (13.7) 275.1 (14.1) 0.252 316.6 (16.6) 320.9 (7.4) 316.9 (4.3) 0.754 0.328 
Distal tibia (33%)        
Cortical vBMD (mg/cm3) 1122.0 (6.6) 1124.6 (6.1) 1129.8 (6.2) 0.090 1173.3 (7.5) 1166.4 (3.2) 1168.6 (1.8) 0.975 0.232 
Total bone mineral content (mg/mm) 378.4 (9.4) 388.9 (8.7) 396.4 (8.8)* 0.012 403.9 (12.6) 415.7 (5.4) 413.4 (3.1) 0.840 0.465 
Cortical thickness (mm) 5.31 (0.14) 5.33 (0.13) 5.54 (0.13)** 0.009 5.19 (0.18) 5.37 (0.08) 5.36 (0.04) 0.595 0.314 
Total area (mm2) 461.8 (11.2) 475.3 (10.3) 474.4 (10.5) 0.241 506.1 (17.7) 515.9 (7.6) 508.0 (4.3) 0.559 0.525 
SSIp (mm3) 2046.7 (71.7) 2126.3 (66.3) 2158.5 (67.3) 0.053 2384.6 (107.8) 2510.7 (46.3) 2458.8 (26.3) 0.800 0.500 
SSIx (mm3) 1278.5 (46.3) 1333.7 (42.8) 1350.9 (43.5) 0.060 1463.0 (73.4) 1549.2 (31.5) 1513.8 (17.9) 0.783 0.382 
Ultra distal tibia (4%)        
Trabecular vBMD (mg/cm3) 224.5 (7.8) 222.3 (7.1) 228.7 (7.2) 0.282 224.0 (10.4) 233.4 (4.5) 226.3 (2.6) 0.475 0.383 
Total bone mineral content (mg/mm) 359.1 (12.2) 359.9 (11.2) 369.3 (11.3) 0.173 374.0 (14.0) 380.5 (6.0) 370.4 (3.4) 0.277 0.215 
Total area (mm2) 1252.8 (34.7) 1253.5 (31.9) 1260.2 (32.3) 0.731 1260.6 (40.3) 1214.1 (17.2) 1204.1 (9.9) 0.225 0.298 
SSIp (mm3) 2215.6(140.6) 2273.6(129.3) 2375.3(131.1) 0.099 2536.4 (154.2) 2606.1 (65.9) 2526.7 (37.7) 0.481 0.231 
SSIx (mm3)  1189.7 (77.0) 1193.3 (70.9) 1242.0 (71.8) 0.267 1264.3 (82.1) 1322.8 (35.1) 1270.1 (20.1) 0.429 0.397 
*p ≤0.050 (Sufficient vs. deficient 25(OH)D, Bonferroni-adjusted ) 
**p ≤0.050 (Sufficient vs. insufficient 25(OH)D, Bonferroni-adjusted)  
All models adjusted for age, BMI, season of blood draw, walk time, caffeine intake, alcohol, smoking, dietary calcium, supplementary calcium, health status, history of 
fracture, diabetes, myocardial infarction, and rheumatoid arthritis 
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5.1 ABSTRACT 
Leptin and adiponectin are hormones secreted by adipose cells that may impact bone mineral density 
(BMD) and modulate bone formation. Few studies have examined the longitudinal association of 
leptin and adiponectin to rates of BMD loss and fracture.  To test the hypothesis that low leptin and 
high adiponectin levels are associated with a higher rate of BMD loss and fracture we studied 3,046 
women and men, aged 70-79, from the Health Aging and Body Composition (ABC) study.  Areal 
BMD (aBMD) of the hip was measured 5 times using dual energy x-ray absorptiometry (DXA) over 
a 10 year period. Random slope and intercept models accounted for within person correlation due to 
repeated hip aBMD measurements. Incident fractures were assessed every 6 months by self-report 
and validated by radiology reports over an average of 6.5 years.  Cox regression was used to estimate 
the hazard ratios for fracture.  Among women, higher adiponectin (p trend=0.019) levels predicted 
greater aBMD loss, but not fracture, after adjusting for covariates including age, race, BMI, and 
weight change.  Conversely, in multivariable models, adiponectin was associated with incident 
fractures in men, but not bone loss.  Men with the highest adiponectin level (tertile 3) had a 207% 
higher risk of fracture (HR=2.07; 95% CI 1.30, 3.30) compared to the lowest tertile (tertile 1), p for 
trend=0.002.  Leptin did not predict fracture risk in men (p trend=0.869) or women (p=0.873) and 
was largely attenuated by BMI.  Results suggest that adiponectin not leptin is a risk factor for bone 
loss and fractures.  Associations for adiponectin also differed by sex with bone loss in women only 
and incident fractures in men.  Future studies are needed to evaluate and explain these sex differences 
of adiponectin with bone loss and fracture.     
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5.2 INTRODUCTION 
Leptin is secreted by adipose cells and has been shown to be highly correlated with body fat 
mass(1), involved in fat metabolism, and appetite control.(2)  At high levels it may increase the 
likelihood of insulin resistance, or metabolic syndrome(3).  Leptin may also have an important 
impact on bone mineral density (BMD),(4) and the modulation of bone formation in humans by 
enhancing differentiation of bone marrow stroma into osteoblasts and inhibiting its 
differentiation into osteoclasts and adipocytes.(5;6)  Some population based cross-sectional 
studies reported that leptin is positively(7-13) associated with BMD, while other results were 
null(14-16) or negative.(17-22) A 12-month longitudinal study in Estonia among 35 older 
women reported that higher leptin predicted lower loss of  whole body BMD.(11)  However, this 
study failed to adjust for measures of adiposity that may have confounded this association.  
Another prospective study (follow-up period 4 years) using the a cohort from Rancho Bernardo 
found that leptin did not predict BMD loss among older women and men.(7) 
   In vivo studies of mice have supported some of these findings by showing an increase 
in BMD after leptin administration.(23-25) Positive effects on BMD were also observed after 
administration of leptin  prevented the fall in plasma osteocalcin observed during a 24-hour and 
5-day starvation study in male mice.(24)  Hemrick et al. found that leptin treatment induced loss 
of bone marrow adipocytes and increased bone formation in leptin-deficient ob/ob mice.(25)  In 
addition, several in vitro studies have shown that higher leptin levels can have a positive effect 
on BMD.(26-28)   
   Adiponectin, another adipocyte derived hormone regulates insulin sensitivity and has 
anti-inflammatory properties.(29;30)  At low levels it has been shown to be associated with 
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various comorbidities including diabetes, myocardial infarction (MI), and atherosclerosis.(31-33) 
Opposite leptin, adiponectin levels are lower among obese individuals.(34) Adiponectin and its 
receptors are expressed in human osteoblasts, suggesting that adiponectin may be a hormone 
linking bone and fat metabolism.(35) However, adiponectin may have negative effects on bone 
by stimulating the receptor activator of nuclear factor-κB ligand (RANKL) pathway and 
inhibiting the production of the decoy receptor for RANKL, osteoprotegerin.(36)  
Several Epidemiological studies reported that lower levels of adiponectin have been 
linked with higher BMD(8;11;37-39) while others have failed to find an association between 
adiponectin and BMD.(16;18;20;20;29;40-42) Three prior studies in the US, Sweden and 
Estonia, evaluated the impact of adiponectin on BMD longitudinally.(11;39;43)  However, the 
study in Sweden(39) only measured BMD once (after an average of 12 years of follow-up) and 
thus did not assess change in BMD over time.  Recently, an additional study in Rancho Bernardo 
failed to find an association between adiponectin and bone loss in older women and men after a 
follow-up period of 4 years.(43)    
Few studies have determined the association of leptin(13;44) and adiponectin(39;43;45) 
to fracture with conflicting results for both.  The aim of this report is to test the hypothesis that 
lower baseline serum leptin levels and higher adiponectin levels will be associated with greater 
hip aBMD loss and a higher risk of a fracture, in older men and women. 
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5.3 METHODS 
5.3.1 Study population 
This study population includes 3,046 women and men (who had serum leptin or adiponectin 
measured) enrolled in the Health Aging and Body Composition (ABC) study, all aged 70-79, at 
baseline from two field centers, Pittsburgh, PA and Memphis, TN.  Among women and men 
enrolled, 46% and 37% were blacks, respectively.  To be eligible to participate in Health ABC, 
subjects had to report no difficulty walking at least 1/4 mile and or climbing a flight of stairs.  
Participants were identified from a random sample of white Medicare beneficiaries and all age-
eligible black community residents in designated ZIP code areas surrounding Pittsburgh and 
Memphis. Exclusion criteria included reported difficulty performing basic activities of daily 
living, obvious cognitive impairment, inability to communicate with the interviewer, intention of 
moving within 3 years, or participation in a trial involving a lifestyle intervention.  The 
institutional review board (IRB) at each center approved the study protocol, and written informed 
consent was obtained from all the participants.  Baseline data were collected from 1997 to 1998. 
5.3.2 Hip aBMD 
Areal BMD (aBMD (g/cm2) of the hip (total and subregions) was measured using DXA (QDR 
4500A; software version 9.03; Hologic, Bedford, MA, USA).  DXA quality assurance 
procedures were conducted at both study sites and monitored by the study Coordinating Center, 
ensuring scanner reliability and identical scan protocols. An anthropometric spine phantom was 
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scanned daily, and a hip phantom was scanned once per week to assess longitudinal performance 
of the scanners.  These measurements were taken at baseline, year 3, year 5/6, year 8, and year 
10.   
5.3.3 Fractures 
Incident fractures were assessed every 6 months by self-report and validated by radiology 
reports.  Adjudication of fractures was complete through June 30, 2007 for the Pittsburgh clinic, 
and through December 31, 2005 for the Memphis clinic.  The average follow-up time was 6.5 
years. Nontraumatic and traumatic fractures were included since both have been linked to low 
BMD.(46)  Pathological fractures and fractures of unknown etiology were excluded. 
5.3.4 Leptin and adiponectin 
Specimens were obtained by venipuncture in the morning after an overnight fast, processed, 
aliquoted into cryovials, frozen at –70°C, and subsequently shipped to the Health ABC Core 
Laboratory at the University of Vermont.  Baseline leptin (N=3020) concentrations were 
measured in duplicate using the Sensitive Human Leptin radioimmunoassy (RIA) Kit (product 
number SHL-81K) from Linco Research, Inc. (St. Charles, MO). The assay is a competitive RIA 
in which the concentration of leptin is determined by competition with 125I-Human Leptin, with 
a maximum detectable leptin level of 50 ng/ml. The intra-assay CV is 3.7–7.5% and the inter-
assay CV is 3.2–8.9%.  Adiponectin (N=3044) was assayed from baseline serum specimens.  
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Total circulating levels of adiponectin were measured in duplicate by RIA (Linco Research, St. 
Charles, MO) with an intra-assay coefficient of variation of 1.8–3.6%.   
5.3.5 Potential confounders 
Demographic variables included self-report of age, race, (black or white), sex, site, and education 
(<HS, HS graduate, or post secondary).  Whole body DXA was also used to measure total lean 
body mass (kg) and body fat (kg).  Weight was measured on a standard balance beam scale to the 
nearest 0.1 kg, and height was measured by a stadiometer to the nearest 0.1 cm. BMI (kg/m2) 
was calculated by using the formula weight (kg) /height2(m2).  Annual weight change (through 
visit 10) was estimated as the weight difference from baseline to the most recent re-assessment 
divided by the respective time.  Lifestyle factors included self-report of smoking (never, current, 
or former), and alcohol consumption (no consumption in last year, <1 drink per week, 1-7 drinks 
per week, or >1 drink per day).  To assess supplementary intake for vitamin D and calcium, and 
non-steroidal anti-inflammatory drug (NSAID) use, participants were asked to bring all 
prescription and over the counter medications, which were coded based on the Iowa Drug 
Information System.(47) To estimate dietary intake of calcium and vitamin D, participants 
completed a 108-item interviewer-administered FFQ (Block Dietary Data Systems, Berkeley, 
CA).  Physical activity (kcal/week) was determined using the caloric expenditure in the past 
week for self-reported walking, climbing stairs, and exercise.(48)  Diabetes was defined using 
fasting glucose (≥126 mg/dl), self-report, or hypoglycemic medication use. Similarly, subjects 
were classified as having hypertension through measurement of blood pressure (systolic ≥140 or 
diastolic ≥90), self-report or antihypertensive medication use. Other medical conditions were 
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determined by asking respondents if they have ever been told by a doctor that they had a specific 
diagnosis of MI and history of fracture after age 45.  Handgrip strength (kg) was measured using 
a hand-held dynamometer (Jamar; TEC, Clifton, NJ). The dynamometer was adjusted for hand 
size for each participant, and two trials were performed on each hand with the maximum value 
recorded as the observation.  
5.3.6 Statistical analysis 
All statistical analyses were performed using the Statistical Analysis System (SAS, version 9.1; 
SAS Institute, Cary, NC).  Two-sample t-tests (Wilcoxon rank-sum test for non-parametric 
measures) and chi-square tests of independence were used to evaluate mean and proportion 
differences by sex.  Leptin and adiponectin means differed in women and men and could not be 
explained by BMI.  Therefore, sex-specific tertiles were used in the analysis (Table 2).  For 
normally distributed variables a test of linear trend was performed by treating leptin or 
adiponectin tertiles as continuous. The Cochran-Armitage test for trend was used for 
dichotomous variables. For non-parametric variables with more than 2 groups the Jonckheere-
Terpstra test of trend was performed.   
Linear mixed-effects models used repeated measures to determine the temporal 
association between leptin, adiponectin and hip aBMD.  These models included a random 
intercept for each subject and a random slope for time to account for within person correlation.  
Participants were excluded if they lacked a baseline hip aBMD measurement or had only one 
measurement during the study.  We estimated the average change in hip aBMD annually by 
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leptin and adiponectin tertiles.  Regression coefficients were estimated for the interaction 
between time and all the independent variables in the model.   
Cox proportional hazards models were used to compare the time to fracture by tertiles 
of leptin and adiponectin and estimate the hazards ratio while controlling for potential 
confounders.  Schoenfeld residuals were used to the test the assumption of proportionality. 
To further explore the dose response relationship between adiponectin and fractures we 
performed spline analysis to test for possible inflection points.  Restricted cubic spline linear 
regression was used with knots for adiponectin at the 5th, 25th, 75th and a reference group at the 
95th percentile was set to create the spline plot.  Threshold effects were evaluated by identifying 
potential inflection points on the spline and performing a test of equality to determine if the 
slopes above and below the cut point are equal.  
Backward elimination procedure was used with the variables age, race, BMI and the 
exposure of interest forced in all the multivariable models.  Weight change was added in the final 
model to determine if this factor better explained our associations.  Multi-collinearity was 
assessed using the variance inflation factor (VIF). Interactions between sex and 
leptin/adiponectin were evaluated.   
5.4 RESULTS 
Table 5-1 shows baseline characteristics by sex.  Women had significantly greater serum leptin 
(21.4 vs. 7.9 ng/ml) and adiponectin levels (13.3 vs. 9.5 μg/ml) than men, p<0.001.  Women 
were also younger, had higher BMI, and total body fat, lower weight change and total lean mass, 
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more likely to never smoke or consume alcohol, had lower dietary vitamin D or calcium intake, 
lower prevalence of diabetes and MI, and lower grip strength than men.  Men (0.97 g/cm2) had 
significantly (p<0.001) higher hip aBMD than women (0.91 g/cm2) at baseline.    
Baseline characteristics by leptin and adiponectin sex-specific tertiles were summarized 
in table 5-2.  Greater serum leptin levels were significantly (p trend<0.05) associated with higher 
BMI, no consumption of alcohol in past year, diabetes, hypertension, and higher aBMD in both 
men and women.  Among women only, increasing leptin tertiles were significantly associated 
with lower age, higher weight change, <HS education, supplementary calcium intake, lower 
dietary and supplementary vitamin D intake, lower physical activity, lower history of fracture 
prevalence, and higher NSAID and grip strength.  The direction of these associations was 
reversed for adiponectin with the exception of NSAID use in women.   
5.4.1 Multivariable Analysis for Hip aBMD Loss 
Table 5-3 summarizes the repeated measures longitudinal association of leptin and adiponectin 
with hip aBMD loss.  Lower levels of adiponectin (p trend=0.023) were associated with lower 
hip aBMD loss in women after adjusting for age, race, BMI, weight change, diabetes and 
baseline hip aBMD.   However, after adjusting for weight change, the association between leptin 
and aBMD loss was no longer significant (p trend=0.134).  Among men, the association of leptin 
and adiponectin with hip aBMD loss was not significant in the unadjusted and adjusted 
regression models.   
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5.4.2 Fractures 
A total of 406 fractures occurred over an average follow-up of 6.4 years.  For women and men 
the fracture rates per 1000 person-years were: 27.5 and 14.0, respectively. Based on the 
unadjusted model, greater leptin levels were significantly (p trend=0.009) associated with lower 
fracture rates, and lower adiponectin concentration predicted (p trend=0.003) higher fracture risk 
in women, table 5-4.  In men, only adiponectin was a significant predictor (p trend=0.001) of 
fracture risk in the unadjusted models.   However, the association of leptin and adiponectin with 
fracture in women was attenuated after adjusting for age, race, and BMI p trend=0.794 and p 
trend=0.658, respectively.  In the full multivariable model, higher adiponectin was associated 
with higher fracture rates in men [(HR=2.07 (95% CI=1.30-3.30), p trend=0.002] after adjusting 
for age, race, BMI, and education. Sex modified (p for interaction=0.017) the association 
between adiponectin tertiles and fracture risk in the full multivariable model.  However, there 
was no evidence of a threshold for serum adiponectin and risk of a fracture in men (p for test of 
threshold>0.05), figure 5-1.  The association between adiponectin and fracture (in men only) was 
fairly linear, and tests of threshold did not approach significance at all adiponectin values.  
5.5 DISCUSSION 
This is the largest and most comprehensive study to evaluate the association of leptin and 
adiponectin to BMD loss and fracture.  Higher adiponectin levels were associated with a higher 
risk of fracture independent of potential confounders including BMI and weight change in men, 
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but not women.  Conversely, lower adiponectin levels predicted lower hip aBMD loss in women 
only.  The impact of leptin on fractures and bone loss was largely explained by BMI and weight 
change in both groups.  
Sex modified the association between adiponectin and fracture.  Men in the highest 
adiponectin tertile had a greater than two fold risk of having fracture than men in lowest tertile. 
This association was independent of BMI, weight change and other covariates of interest.  In 
contrast, adiponectin levels were unrelated to fracture risk in women.  BMI and weight change 
were associated with fracture among women, but not in men.  Our results were similar to Rancho 
Bernardo Study which reported an association between adiponectin and vertebral fractures 
[adjusted OR:1.13; 95% CI:1.08-1.23, p=0.009] in men not women.(43)  Participants of the 
Rancho Bernardo Study were similar to our subjects in age and smoking prevalence, but had 
lower BMI, fat mass, adiponectin and prevalence of diabetes.  Also, consistent with our findings, 
a cross-sectional study in Japan among 231 men and 170 post-menopausal Japanese women, 
reported that one standard deviation difference in adiponectin was associated with higher odds of 
vertebral fracture in men, but not women.(45)  In contrast, a recent prospective study (15 year 
follow-up) in Sweden, did not find an association adiponectin levels and fracture, among 507 
men aged 70 and older.(39)  The study population in Sweden had similar characteristics related 
to age, BMI, and serum adiponectin levels. The results of the spline analysis among men, 
suggested that this association was very linear with no evidence of an adiponectin threshold for 
fracture risk.  In the recent Swedish study (which found no association), the authors did not 
report tests for thresholds. However, based on their spline plot there appears to be no major 
changes in trajectory of the curve indicating a lack of a potential threshold effect.(39)  
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A recent study reported that recombinant adiponectin induced RANKL and inhibited 
OPG mRNA expression in human osteoblasts in a dose and time dependent manner leading to 
osteoclast formation.(36)  The risk of bone loss and fracture was higher with greater levels of 
adiponectin perhaps reflecting greater osteoclast activation and bone resorption. Population 
based longitudinal studies evaluating the association of adiponectin and markers of bone 
turnover are needed.   
 Leptin did not predict incident fractures, in men or women, and the association was 
largely attenuated by BMI.  A ten year cohort study among 250 Italian women and men with 
comparatively lower leptin levels reported that subjects in the highest leptin tertile had a 
significantly reduced risk of a non-traumatic fracture when compared to the lowest tertile group 
after adjusting for weight and other confounders.(44)  However, this study included relatively 
younger participants (mean age 58.5 years), and a small number of cases (N=31). Higher leptin 
levels were also associated with a lower prevalence of vertebral fractures independent of percent 
fat, among 139 Japanese postmenopausal women, aged 48-78.(13)  The two previous studies 
have relatively younger cohorts and older age is associated with a greater number of 
comorbidities. Therefore, age and other covariates (BMI, weight change, grip strength) in our 
study were able to explain fracture risk better than leptin levels. 
 After adjusting for weight change, the association between leptin and hip BMD loss, 
was no longer significant.  Past cross-sectional associations reports have shown that leptin is 
positively associated with BMD(8-10;12;13). Few prior studies have assessed the impact of 
leptin on BMD longitudinally.(7;11)  A twelve month prospective study in Estonia among 35 
women mean age 69.7 years, reported that higher leptin was correlated with lower loss of whole 
body aBMD.(11)  However, this study did not adjust for measures of adiposity.  The Rancho 
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Bernardo study found that leptin (measured on average 4 years before BMD) predicted higher 
femoral neck, total hip, lumbar spine, and radial aBMD in women but men.  Consistent with our 
findings, they failed to find an association between leptin and hip aBMD loss (2 BMD 
measurements over 4 years). 
 Higher adiponectin levels were associated with greater hip aBMD loss, in women, but 
not men. There have been several cross-sectional studies that have reported that adiponectin is 
inversely associated with BMD.(8;11;37;38). Three prospective studies found an inverse 
association between adiponectin and BMD.(11;39;43)  The study in Estonia (did not control for 
measures of adiposity) reported that higher adiponectin was associated with higher aBMD loss of 
the lumbar spine.(11)  The Swedish longitudinal study reported that higher adiponectin 
(measured on average 12 years before BMD) was associated with lower aBMD of lumbar spine, 
proximal femur and whole body in older men and women.(39)  However, this study did not 
adjust for BMI or body composition measures and failed to assess longitudinal change in BMD 
over time.  Finally the Rancho Bernardo study found that adiponectin (measured on average 4 
years before BMD) predicted lower femoral neck, total hip, and radial aBMD in women and 
men.(7)  However, adiponectin was not associated with bone loss in the Rancho Bernardo Study 
at any of these sites in men or women.  Prior studies have shown that the most rapid bone loss 
occurs between the ages of 40 and 55, therefore 4 years of follow-up and a mean age of 75 years 
may explain their null finding.(49;50)  
It is uncertain why there are sex differences for the association of adiponectin with bone 
loss and incident fractures.  Adiponectin was 40% higher in women compared to men.  However, 
it is uncertain if sex differences in adiponectin account for these differential associations.  BMI 
and weight change explained fracture risk in women; however in men these variables did not 
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predict fractures. Consistent with our findings, a previous study in mice showed that there was a 
stronger inverse correlation for adiponectin and bone mass in females compared to males.(51) 
Prior studies suggest that the association between adiponectin and bone may be influenced by 
sex hormones.(43)  Future prospective studies that control for sex hormones are needed.     
Study had several potential limitations. We measured serum leptin and adiponectin at 
baseline only.  In addition, survivors may have greater BMD than non-survivors(52), and study 
participants are likely to be healthier than the general population.  Finally, we adjusted for many 
covariates, but residual confounding remains a potential limitation. Strengths of this study 
include a large sample size, reliable ascertainment of exposure (leptin, adiponectin) and outcome 
(fracture, hip aBMD) data, adjustment for many potential confounders, long follow-up period, 
and multiple time points for assessment of hip aBMD data. 
In summary, in a large cohort of men and women, greater adiponectin levels were 
associated with a higher fracture risk in men, but not women, after controlling for multiple 
confounders including measures of adiposity.  Conversely, adiponectin was associated with bone 
loss in women only.  This study provides evidence that adiponectin, though not leptin, may 
clinically impact BMD loss and fracture rates.  Future studies are needed to evaluate and explain 
these sex differences of adiponectin with bone loss and fracture.     
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Figure 5-1 Restricted cubic spline plots in men for hazard ratio of fracture by adiponectin (µg/ml)
5.7 TABLE AND FIGURES
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                       Table 5-1 Characteristics among older women and men 
 Women (N=1478) Men (N=1568) P-value 
Leptin (ng/ml), mean (SD)   21.4 ± 14.7 7.9 ± 6.9 <0.001 
Adiponectin (μg/ml), mean (SD)   13.3 ± 7.4 9.5 ± 5.6 <0.001 
Age (years), mean (SD)   73.5 ± 2.9 73.8 ± 2.9 0.013 
BMI (kg/m2), mean (SD) 27.7 ± 5.5 27.1 ± 4.0 <0.001 
Weight change (kg), mean (SD) -0.37 ± 1.74 -0.40 ± 1.94 <0.001 
 Total fat mass (kg), mean (SD) 29.2 ± 9.3 24.2 ± 7.2 <0.001 
Total lean mass (kg), mean (SD) 41.3 ± 6.2 57.1 ± 7.3 <0.001 
Race, % 
  Caucasians 
  African Americans 
 
53.9 
46.1 
 
63.2 
36.8 
<0.001 
 Education, % 
  <HS 
  HS graduate 
  Post secondary 
 
23.2 
39.5 
37.3 
 
27.3 
25.5 
47.2 
<0.001 
Site, % 
  Memphis 
  Pittsburgh 
 
50.1 
49.9 
 
50.4 
49.6 
0.885 
Smoking, % 
  Never 
  Current 
  Former 
 
57.2 
9.9 
32.9 
 
29.4 
10.8 
59.8 
<0.001 
Alcohol, % 
  No consumption in last year 
  < 1 per week 
  1-7 per week 
  >1 per day 
 
57.7 
21.9 
16.9 
3.5 
 
42.6 
19.6 
26.2 
11.6 
<0.001 
Dietary calcium (mg/day), mean (SD) 753.2 ± 363.6 817.3 ± 428.9 <0.001 
Supplementary calcium, % 28.4 7.2 <0.001 
Dietary vitamin D (IU/day), mean (SD) 192.6 ± 131.1 225.9 ± 147.5 <0.001 
Supplementary vitamin D, % 13.4 3.4 <0.001 
Physical activity (kcal/week), median (IQR) 298.5 (26.7-920.4) 688.0 (165.1-1832.1) <0.001 
History of fracture after  age 45, % 27.4 16.1 <0.001 
Diabetes, % 16.3 22.0 <0.001 
Hypertension, % 77.6 74.0 0.020 
MI, % 17.9 22.4 0.051 
NSAID use, % 25.2 18.4 <0.001 
Grip strength (kg), mean (SD) 25.1 ± 6.3 40.8 ± 8.6 <0.001 
Hip aBMD (g/cm2) 0.81 ± 0.15 0.97 ± 0.15 <0.001 
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   Table 5-2 Characteristics by leptin and adiponectin tertiles in older women and men 
 Leptin Adiponectin 
 Low Middle High P Trend Low Middle High P 
Trend 
Women N=518 N=517 N=517 N=562 N=501 N=505 
Leptin (ng/ml) 0.3-12.4 12.5-24.1 24.2-99.3 <0.001 - - - 
Adiponectin (μg/ml) - - - 1.0-9.0 10.0-15.0 16.0-49.0 <0.001 
Age (years), mean (SD)   73.8 ± 3.0 73.5 ± 2.8 73.2 ± 2.8 0.001 73.1 ± 2.8 73.4 ± 2.8 74.1 ± 2.9 <0.001 
BMI (kg/m2), mean (SD) 23.7 ± 3.9 27.4 ± 4.0 31.8 ± 5.0 <0.001 30.1 ± 5.4 27.5 ± 5.1 25.3 ± 4.8 <0.001 
Weight change (kg), mean (SD) -0.22 ± 1.39 -0.30 ± 1.67 -0.56  ± 2.07 0.002 -0.40 ± 1.50 -0.31 ± 1.35 -0.38 ± 2.25 0.780 
Total fat mass (kg), mean (SD) 22.1 ± 6.7 28.6 ± 6.1 36.7 ± 8.4 <0.001 32.5 ± 9.3 29.3 ± 8.8 25.4 ± 8.3 <0.001 
Total lean mass (kg), mean (SD) 38.3 ± 5.0 40.9 ± 5.7 44.6 ± 6.0 <0.001 44.1 ± 6.3 40.8 ± 5.8 38.7 ± 5.1 <0.001 
Race, % 
  Caucasians 
  African Americans 
 
68.0 
32.0 
 
55.3 
44.7 
 
39.1 
60.9 
<0.001  
29.9 
70.1 
 
61.9 
38.1 
 
72.9 
27.1 
<0.001 
Education, % 
  <HS 
  HS graduate 
  Post secondary 
 
18.0 
40.1 
41.9 
 
21.8 
42.2 
37.0 
 
29.6 
37.4 
33.0 
<0.001  
33.1 
37.2 
29.7 
 
17.7 
42.8 
39.6 
 
17.8 
38.8 
43.4 
<0.001 
Site, % 
  Memphis 
  Pittsburgh 
 
47.7 
52.3 
 
46.8 
53.2 
 
56.1 
43.9 
0.007  
48.0 
52.0 
 
49.7 
50.3 
 
52.9 
47.1 
0.117 
Smoking, % 
  Never 
  Current 
  Former 
 
58.7 
13.5 
27.8 
 
54.9 
11.0 
34.0 
 
57.7 
5.2 
37.1 
0.136  
53.0 
10.9 
36.1 
 
58.0 
8.8 
33.2 
 
61.1 
9.9 
29.0 
0.007 
Alcohol, % 
  No consumption in last year 
  < 1 per week 
  1-7 per week 
  >1 per day 
 
54.3 
21.9 
19.7 
4.1 
 
55.9 
22.8 
16.6 
4.7 
 
62.6 
21.1 
14.5 
1.8 
0.002  
65.1 
20.8 
11.2 
2.9 
 
54.2 
22.8 
20.0 
3.0 
 
52.8 
22.2 
20.2 
4.8 
<0.001 
Dietary calcium (mg/day), mean (SD) 788.1 ± 375.0 732.7 ± 357.2 743.9 ± 358.7 0.065 764.5 ± 388.6 729.2 ± 345.2 764.5 ± 352.9 0.970 
Supplementary calcium, % 37.7 26.4 21.1 <0.001 20.4 30.5 35.1 <0.001 
Dietary vitamin D (IU/day), mean (SD) 212.8 ± 140.2 178.3 ± 123.5 186.7 ± 127.4 0.002 192.9 ± 134.4 184.9 ± 122.7 199.7 ± 135.2 0.450 
Supplementary vitamin D, % 18.7 12.0 8.7 <0.001 9.8 12.6 17.3 <0.001 
Physical activity (kcal/week), median (IQR) 425 (55-1040) 289 (47-895) 213 (5-788) <0.001 207 (8-793) 343 (42-1025) 371 (70-898) 0.001 
History of fracture after  age 45, % 30.9 27.3 24.0 0.013 20.7 27.7 34.5 <0.001 
Diabetes, % 10.7 16.0 21.9 <0.001 30.1 10.7 6.3 <0.001 
Hypertension, % 72.0 78.1 82.2 <0.001 84.3 76.5 71.3 <0.001 
MI, % 8.3 8.3 6.6 0.299 7.8 9.0 6.7 0.529 
NSAID use, % 21.0 26.0 27.9 0.011 23.6 24.5 27.6 0.140 
Grip strength (kg), mean (SD) 24.4 ± 6.3 25.2 ± 6.1 25.5 ± 6.4 0.003 26.2 ± 5.7 24.9 ± 6.3 24.0 ± 6.7 <0.001 
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Hip aBMD (g/cm2) 0.75 ± 0.14 0.80 ± 0.13 0.88 ± 0.14 <0.001 0.87 ± 0.14 0.80 ± 0.14 0.75 ± 0.14 <0.001 
Men N=488 N=491 N=489 N=519 N=452 N=505 
Leptin (ng/ml) 0.1-4.3 4.4-8.4 8.5-60.3 <0.001 - - - 
Adiponectin (μg/ml) - - - 1.0-6.0 7.0-10.0 11.0-53.0 <0.001 
Age (years), mean (SD)   73.8 ± 2.9 73.7 ± 2.8 73.7 ± 2.9 0.307 73.4 ± 2.8 73.7 ± 2.9 74.1 ± 2.9 <0.001 
BMI (kg/m2), mean (SD) 24.2 ± 2.8 27.1 ± 3.0 29.9 ± 3.8 <0.001 28.1 ± 3.7 27.1 ± 3.9 26.0 ± 4.0 <0.001 
Weight change (kg), mean (SD) -0.33 ± 2.18 -0.36 ± 1.67 -0.51 ± 1.94 0.163 -0.43 ± 1.81 -0.38 ± 2.18 -0.37 ± 1.84 0.615 
Total fat mass (kg), mean (SD) 18.2 ± 4.4 24.4 ± 4.8 29.8 ± 6.9 <0.001 25.2 ± 6.8 24.6 ± 7.0 22.7 ± 7.5 <0.001 
Total lean mass (kg), mean (SD) 54.2 ± 6.3 57.3 ± 6.9 59.7 ± 7.7 <0.001 58.8 ± 7.4 57.3 ± 7.2 55.1 ± 6.9 <0.001 
 Race, % 
  Caucasians 
  African Americans 
 
63.3 
36.7 
 
68.0 
32.0 
 
57.9 
42.1 
0.078  
49.3 
50.7 
 
64.8 
35.2 
 
76.2 
23.8 
<0.001 
Education, % 
  <HS 
  HS graduate 
  Post secondary 
 
30.0 
24.6 
45.4 
 
26.1 
25.9 
48.0 
 
26.0 
26.0 
48.0 
0.248  
30.1 
27.8 
42.1 
 
24.6 
24.8 
50.6 
 
26.7 
24.0 
49.3 
0.033 
Site, % 
  Memphis 
  Pittsburgh 
 
46.5 
53.5 
 
52.3 
47.7 
 
52.8 
47.2 
0.049  
48.9 
51.1 
 
48.0 
52.0 
 
53.9 
46.1 
0.117 
Smoking, % 
  Never 
  Current 
  Former 
 
31.1 
16.0 
52.9 
 
27.8 
8.6 
63.6 
 
29.9 
7.5 
62.6 
0.023  
29.7 
10.4 
58.9 
 
33.0 
11.7 
55.3 
 
25.8 
10.3 
63.8 
0.174 
Alcohol, % 
  No consumption in last year 
  < 1 per week 
  1-7 per week 
  >1 per day 
 
39.0 
19.7 
29.1 
12.2 
 
43.4 
20.1 
25.8 
10.7 
 
45.4 
19.2 
23.5 
11.9 
0.051  
47.1 
21.7 
22.3 
8.9 
 
41.1 
20.7 
25.3 
12.9 
 
39.3 
16.4 
30.9 
13.4 
<0.001 
Dietary calcium (mg/day), mean (SD) 824.4 ± 431.3 807.5 ± 416.9 820.0 ± 440.5 0.878 802.1 ± 441.3 822.4 ± 445.1 828.0 ± 401.8 0.355 
Supplementary calcium, % 7.6 6.7 7.4 0.887 5.6 7.8 8.3 0.089 
Dietary vitamin D (IU/day), mean (SD) 225.8 ± 151.6 221.7 ± 138.7 230.8 ± 152.9 0.630 222.7 ± 153.4 221.6 ± 146.2 232.2 ± 142.2 0.330 
Supplementary vitamin D, % 2.5 3.3 4.5 0.080 2.5 3.6 4.2 0.142 
Physical activity (kcal/week), median (IQR) 766 (189-1977) 657 (121-1840) 647 (178-1715) 0.279 579 (148-1539) 794 (172-2003) 761 (178-1944) 0.070 
History of fracture after  age 45, % 17.2 14.9 16.0 0.591 16.6 14.9 16.6 0.983 
Diabetes, % 15.2 22.0 28.9 <0.001 35.0 19.4 11.2 <0.001 
Hypertension, % 72.3 70.5 78.9 0.019 76.5 75.0 70.9 0.041 
MI, % 16.8 12.5 17.6 0.715 16.6 16.6 13.7 0.211 
NSAID use, % 17.7 18.3 19.1 0.583 16.7 17.8 20.8 0.094 
Grip strength (kg), mean (SD) 40.9 ± 9.1 40.9 ± 8.4 40.6 ± 8.4 0.595 41.9 ± 8.7 41.0 ± 8.9 39.5 ± 8.2 <0.001 
Hip aBMD (g/cm2) 0.93 ± 0.15 0.97 ± 0.14 1.02 ± 0.15 <0.001 1.02 ± 0.15 0.98 ± 0.14 0.92 ± 0.15 <0.001 
          
 
 
    Table 5-2 continued. 
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Table 5-3 The association between sex-specific tertiles of leptin/diponectin and hip aBMD lossa using linear mixed-effects regression models  
  Leptin   Adiponectin  
 Low Middle High P 
Trend 
Low Middle High P 
Trend 
Women       
Unadjusted -0.52 (-0.60, -0.44) -0.43 (-0.51, -0.34) -0.60 (0.69, -0.51) 0.983 -0.50 (-0.57, -0.42) -0.47 (-0.56, -0.39) -0.57 (-0.66, -0.48) 0.886 
Age adjusted -0.51 (-0.59, -0.44) -0.43 (-0.51, -0.47) -0.62 (-0.71, -0.53) 0.758 -0.51 (-0.59,-0.44) -0.49 (-0.57, -0.49) -0.55 (-0.65, -0.46) 0.518 
Age and race adjusted   -0.57 (-0.65, -0.49) -0.44 (-0.53, -0.36) -0.57 (-0.66, -0.48) 0.178 -0.43 (-0.51, -0.36) -0.55 (-0.61, -0.44) -0.65 (-0.74, -0.55) 0.043 
Age race and BMI adjusted   -0.61 (-0.70, -0.52) -0.45 (-0.53, -0.36) -0.52 (-0.63, -0.42) 0.021 -0.42 (-0.50,-0.34) -0.53 (-0.61, -0.44) -0.66 (-0.76, -0.57) 0.015 
Base model† -0.62 (-0.71, -0.53) -0.45 (0.53, -0.36) -0.53 (-0.64, -0.43) 0.023 -0.41 (-0.50, -0.33) -0.53 (-0.62, -0.44) -0.70 (-0.80, -0.59) 0.005 
Base model† + weight change -0.60 (-0.70, -0.51) -0.46 (-0.55, -0.37) -0.57 (-0.68, -0.46) 0.134 -0.43 (-0.51, -0.35) -0.56 (-0.64, -0.47) -0.67 (-0.77, -0.58) 0.019 
Men       
Unadjusted -0.61 (-0.68, -0.53) -0.54 (-0.62, -0.46) -0.56 (0.65, -0.48) 0.089 -0.55 (-0.62, -0.48) -0.51 (-0.59, -0.43) -0.66 (-0.74, -0.57) 0.439 
Age adjusted -0.61 (-0.68, -0.53) -0.55 (-0.62, -0.47) -0.57 (-0.65, -0.49) 0.101 -0.56 (-0.64, -0.49) -0.51 (-0.59, -0.43) -0.65 (-0.73, -0.56) 0.234 
Age and race adjusted   -0.61 (-0.69, -0.54) -0.56 (-0.63, -0.48) -0.56 (-0.65, -0.48) 0.064 -0.54 (-0.61, -0.46) -0.53 (-0.61, -0.45) -0.68 (-0.77, -0.60) 0.149 
Age race and BMI adjusted   -0.59 (-0.67, -0.50) -0.56 (-0.63, -0.48) -0.59 (-0.68, -0.50) 0.440 -0.54 (-0.62, -0.47) -0.53 (-0.61, -0.45) -0.67 (-0.76, -0.58) 0.278 
Base model‡  -0.56 (-0.65, -0.46) -0.58 (-0.66, -0.49) -0.67 (-0.78-0.57) 0.490 -0.55 (-0.63, -0.47) -0.55 (-0.64, -0.47) -0.71 (-0.80, -0.62) 0.147 
Base  model‡ + weight change -0.60 (-0.69, -0.51) -0.58 (-0.66, -0.50) -0.60 (-0.70-0.51) 0.427 -0.55 (-0.63, -0.47) -0.54 (-0.63, -0.47) -0.70 (-0.79, -0.61) 0.148 
                a Mean annualized % change in aBMD (95% CI) 
                †Adjusted for age, age*time, race, race*time, BMI, BMI*time, diabetes*time, and baseline hip aBMD 
                ‡ Adjusted for age, age*time, race, race*time, BMI, BMI*time, physical activity, lean mass*time, total fat*time, and baseline hip aBMD  
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Table 5-4 Cox proportional hazards modela according to sex-specific tertiles of leptin (ng/ml) and adiponectin (μg/ml)  
 Leptin   Adiponectin   
 Low Middle High P Trend Low Middle High P Trend 
Women       
Unadjusted (Ref) 0.74 (0.56-0.98) 0.68 (0.51-0.92) 0.009 (Ref) 1.55 (1.14-2.11) 1.61 (1.19-2.19) 0.003 
Age adjusted (Ref) 0.75 (0.56-0.99) 0.70 (0.52-0.94) 0.015 (Ref) 1.52 (1.12-2.08) 1.56 (1.14-2.12) 0.006 
Age and race adjusted   (Ref) 0.80 (0.60-1.06) 0.84 (0.62-1.44) 0.217 (Ref) 1.24 (0.90-1.72) 1.19 (0.86-1.66) 0.369 
Age race and BMI adjusted   (Ref) 0.86 (0.63-1.16) 0.98 (0.67-1.41) 0.794 (Ref) 1.19 (0.86-1.66) 1.11 (0.79-1.56) 0.658 
Base  model† (Ref) 0.86 (0.63-1.16) 0.96 (0.66-1.39) 0.732 (Ref) 1.17 (0.84-1.64) 1.08 (0.76-1.53) 0.796 
Base  model† + weight change (Ref) 0.85 (0.62-1.17) 0.99 (0.68-1.45) 0.873 (Ref) 1.12 (0.79-1.57) 0.96 (0.70-1.42) 0.869 
Men       
Unadjusted (Ref) 0.89 (0.59-1.33) 0.70 (0.45-1.09) 0.118 (Ref) 1.44 (0.88-2.35) 2.30 (1.48-3.58) <0.001 
Age adjusted (Ref) 0.90 (0.60-1.35) 0.72 (0.46-1.12) 0.146 (Ref) 1.41 (0.86-2.31) 2.22 (1.43-3.47) <0.001 
Age and race adjusted   (Ref) 0.90 (0.60-1.35) 0.75 (0.49-1.17) 0.209 (Ref) 1.35 (0.82-2.21) 2.00 (1.27-3.14) 0.002 
Age race and BMI adjusted   (Ref) 0.94 (0.61-1.46) 0.82 (0.48-1.39) 0.467 (Ref) 1.34 (0.82-2.19) 1.95 (1.23-3.08) 0.004 
Base  model‡ (Ref) 0.87 (0.56-1.36) 0.75 (0.44-1.28) 0.731 (Ref) 1.35 (0.82-2.21) 2.04 (1.28-3.23) 0.002 
Base  model‡ + weight change Ref) 0.85 (0.54-1.33) 0.72 (0.42-1.25) 0.242 (Ref) 1.29 (0.78-2.13) 2.07 (1.30-3.30) 0.002 
                aValues are hazard ratios (95% CI); 
                †Adjusted for age, race, BMI, education, history of fracture, and grip strength 
                ‡ Adjusted for age, race, BMI, and education 
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6.0  GENERAL DISCUSSION 
6.1 SUMMARY 
This dissertation identified factors associated with fracture, bone mineral density, bone geometry 
and bone strength in older adults.  The aims of this dissertation project were: 1) examine 
correlates of trabecular and cortical vBMD of the radius and tibia in primarily older community 
dwelling Caucasian men and test the hypothesis that the correlates differ; 2) Test the hypothesis 
that higher levels of serum 25(OH)D will be positively associated with vBMD, bone geometry, 
and bone strength measures in men of Caucasian and African heritage; 3) and test the hypothesis 
that higher baseline serum leptin levels and lower adiponectin levels will be associated with a 
lower risk of fracture and slower rates of bone loss in women and men.  
In the first study, our multivariable models explained up to 10% of the variance in 
trabecular vBMD and up to 9% of the variance in cortical vBMD.  These results suggest that 
there are unknown factors, possibly genetic, related to vBMD in older men that we have yet to 
identify.  Also, fewer correlates were identified for trabecular vBMD of the radius when 
compared to tibial trabecular vBMD.  The tibia is a major weight bearing site compared to the 
radius, so variables such as weight and physical function may exert a greater influence on 
vBMD.   
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Correlates of trabecular and cortical vBMD differed.  Higher body weight was associated 
with greater trabecular vBMD and lower cortical vBMD.  Increased mechanical loads have been 
shown to lead to bone microdamage, increased bone turnover, which may explain the reduction 
in cortical vBMD.  Height was negatively associated with lower trabecular vBMD and previous 
studies show that taller individuals may experience greater height loss than others.  A positive 
correlation for education and trabecular vBMD was reported which may be a result of residual 
confounding.  Smoking was significantly associated with lower cortical vBMD.  Previous reports 
hypothesize that smoking can possibly lower BMD by decreasing calcium absorption or 
inhibiting the proliferation of osteoprogenitor cells, and influence estrogen metabolism.  
Surprisingly, diabetic men using TZD medication had greater trabecular vBMD at both skeletal 
sites.  Greater weight among TZD users compared to diabetic men with and non-diabetic men 
(95.3 kg vs. 82.9 kg, p<0.001) may have contributed to this findings.  RA was unexpectedly 
associated with greater cortical vBMD of the radius.  Androgen replacement therapy was 
associated with higher cortical vBMD at both skeletal sites and anti-androgen use was 
independently correlated lower trabecular vBMD of the tibia.  Finally, lower grip strength was 
associated with lower cortical vBMD at the radius and using arms to stand from a chair was 
associated with lower trabecular vBMD.
Several variables were correlated with both cortical and trabecular vBMD.  Age was 
significantly associated with lower vBMD at all sites with the exception of the trabecular site at 
the radius.  A substantial loss in trabecular vBMD of the radius and tibia has been shown to 
occur before mid-life (age 20-49). Caffeine intake was associated with lower vBMD.  Caffeine 
may reduce BMD by decreasing intestinal calcium absorption, but it may be a marker for lower 
calcium consumption.  Total calcium intake was positively correlated with vBMD.  An adequate 
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intake of calcium can ameliorate the progressive loss of bone with age.   History of non-trauma 
fracture was strongly associated with lower vBMD at all sites.  Hypertension was positively 
correlated with vBMD.  A positive association may have arisen from confounding by the use of 
certain medications such as thiazide (TZ) diuretics that may increase BMD due to their ability to 
improve calcium retention. 
Some factors were not associated with cortical or trabecular vBMD that have been shown 
to be correlated to BMD in past studies.  Most medication variables were not correlated with 
vBMD.  The prevalence of medication use (example SSRI) was relatively low therefore power 
was a limitation for some covariates.  Other correlated identified in past studies that were null 
include alcohol use, physical activity and hyperthyroidism (very low prevalence).        
In the second study, serum 25(OH)D was significantly (p<0.001) higher in men of 
African descent (34.7 ng/ml)  versus Caucasians (27.6 ng/ml).  African Americans typically have 
lower levels of serum 25(OH)D than Caucasians across all age groups and both genders. 
However, mean 25(OH)D concentrations in the tropical regions of the African continent have 
been shown to compare well to the Tobago and MrOS populations high.  Men of Caucasian and 
African descent differed in the association of serum 25(OH)D levels to indices of bone strength.  
At the distal radius greater 25(OH)D had a positive impact on bone measures (cortical vBMD, 
total BMC, cortical thickness, and strength strain index) in Caucasians and a negative or null 
effect on these parameters in men of African descent. However, at the ultra distal radius, and 
specifically for trabecular vBMD, 25(OH)D sufficiency was associated with lower vBMD in 
Caucasians and greater vBMD in men of African descent.   In men of African descent no 
associations were found with the exception of total bone area at the distal radius, and axial 
strength strain index, which were significantly lower in 25(OH)D sufficient subjects.  It is 
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currently unknown why men of African descent would show lower bone size and strength with 
higher 25(OH)D.  Blacks have been shown to be resistant to the anti-resorptive effects of PTH 
which were found to be lower in men of African descent. Also, PTH has been shown to stimulate 
osteoblastic bone formation at the periosteal surface and postpone osteoblast apoptosis resulting 
in greater bone area and cortical thickness and thus bone strength.  Serum 25(OH)D thresholds 
were identified among Caucasians, at approximately 20 ng/ml, for tibial total BMC and tibial 
cortical thickness, respectively.  Indicating that after this level the effects on bone are minimal.  
The validity of older 25(OH)D values has been questioned due to the use of insensitive and 
unreliable radioimmunoassay-based methods which were fraught with inaccuracies due to 
protein binding artifacts.  Thus, direct comparison of our 25(OH)D concentrations with other 
studies is difficult because different cut points have been used to define deficiency/insufficiency, 
and values were derived using different assay methods.  
In the third study, the adiponectin hormone, not leptin, was a strong independent (HR:2.0) 
determinant of fracture.  After stratifying by gender, this association was confined to older men, 
not women.  The hazard of a fracture in the high adiponectin tertile was approximetley 200% 
higher than the lowest tertile in men.  There did not appear to be any threshold effect of 
adiponectin on fracture in men.  The associations between adiponectin and BMD loss were only 
significant among women. The impact of leptin on fractures and BMD was largely attenuated by 
BMI (leptin was strongly correlated with BMI) and weight change.  Introduction of recombinant 
adiponectin to human osteoblasts has been shown to induce osteoblast formation, as well as 
stimulate the osteoclast RANKL pathway while inhibiting its decoy receptor, OPG in a dose and 
time dependent manner leading to osteoclast formation. It’s possible that subjects in the highest 
tertile for adiponectin had greater osteoclast activation and bone resorption.                          
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6.2  FUTURE RESEARCH DIRECTIONS 
Despite the larger number of potential correlates of vBMD that we examined in chapter 3, our 
regression models explained  an estimated 10% of the variation in trabecular and cortical vBMD.  
 The heritability of BMD was shown to be rather high, at 59% to 73%, for trabecular and 17% to 
42%, for cortical vBMD.(4-6)  Thus it is likely that a larger portion of the unexplained variance 
reflects genetic factors that were not accounted for in the analysis.  Comprehensive genetic 
studies of trabecular and cortical vBMD are needed and are underway. In MrOS, a large genetic 
wide association study (GWAS) has recently been funded and will include analyses of over one 
million single nucleotide polymorphisms (SNPS) that is intended to identify  important genes that 
contribute to vBMD.  Yerges at al. recently reported that trabecular vBMD and cortical vBMD 
are under different genetic control.(7)  Consistent with this observation we found that 
demographic, anthropometric, medical, and lifestyle correlates also differ for trabecular and 
cortical vBMD.  In addition to the lack of genetic studies for trabecular and cortical vBMD, there 
is a dearth of studies that included sex hormones, markers of bone formation or resorption, and 
other biochemical markers including 25(OH)D, and PTH.       
One of the more interesting observations was that weight was associated with greater 
trabecular vBMD, but lower cortical vBMD.  Similar observations have been shown in two prior 
studies using QCT measurements in men.(8;9)  Increased mechanical load due to having greater 
fat and lean mass may paradoxically lead to bone microdamage, increased bone turnover, and a 
transient reduction in cortical vBMD.(10) Also, individuals who are obese may adapt by 
increasing periosteal bone diameter requiring lower cortical density to maintain the same 
strength.(11)  In women, a meta-analysis determined the association of weight and hip fractures 
112 
 
and concluded that lower weight increased the risk of hip fracture.(12) In men, the  
association for weight and hip fractures is not well understood.  A previous study using older 
white men from NHANES I  showed that BMI at baseline did not differ among individuals with 
and without a hip fracture after 14 years of follow-up(13)  Conversely, a study among 730 men 
from 14 centers in Southern Europe did find that lower BMI was a risk factor for hip 
fracture.(14)  Future research could investigate the longitudinal impact of weight on cortical 
bone loss (various sites including distal radius, distal tibia, and femoral neck), and fractures of 
the hip (including femoral neck, femoral head, intertrochanteric and subtrochanteric fractures).  
We hypothesize that an increase of one standard deviation in weight will be associated with an 
increase in cortical vBMD loss and hip fractures in men.   
Past studies(15;16) indicated that TZD use was associated with increased BMD loss; we 
found a positive correlation for TZD use and trabecular vBMD at the radius and tibia.  Yaturu et 
al. in a cohort of 160 men found that TZD users had significantly greater femoral neck, and total 
hip aBMD loss than non-TZD men who had diabetes.(16)  However, a major limitation of this 
study is that it did not adjust for any potential confounders.  Shwartz et al. found that TZD users 
had higher lumbar spine aBMD loss than non-users among diabetics, in women, but not 
men.(15)  The former report may suggest that gender may modify this association.  A case-
control study of diabetics found that the odds of nonvertebral (hip, wrist and humorous) fracture 
was significantly higher among TZD uses compared with non-users.  However, they found no 
association for vertebral fractures.(17)  Also, the previous study only identified 59 vertebral 
fractures; therefore a cohort with a larger incidence of vertebral fracture is needed.  TZD users in 
our study had significantly greater weight than non-diabetics, and non-TZD users who were 
diabetics although we adjusted for weight.  Future studies should evaluate if this finding reflects 
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a physiological mechanism that is unique to trabecular vBMD. We propose a prospective 
analysis among diabetic men that follows TZD users and compares them to non-TZD users.  We 
hypothesize that TZD users will have a lower rate of trabecular vBMD loss and vertebral 
fractures after adjusting for measures related to body composition.       
In chapter 4 we examined the association of serum 25(OH)D and indices of bone strength 
in older men of Caucasian and African descent.  Race cohort modified the association between 
25(OH)D and indices of bone strength.  Among Caucasian men, serum 25(OH)D was positively 
associated with pQCT measures at the distal (cortical regions), but not ultra distal (trabecular 
regions) radius and tibia.  In men of African descent, 25(OH)D was negatively correlated with 
total bone area and axial strength index at the distal radius.   
This raises the possibility of differential associations between 25(OH)D and indices of 
bone strength by race.  The association of 25(OH)D with indices of bone strength is still not well 
understood, and has been understudied(18;19) in individuals of African descent.  The proportion 
of European admixture in US African American men is much higher than in Afro-Caribbean men 
we studied, which may be influencing the findings.  The men in our study are genetically more 
homogeneous (have 4 grandparents of African ancestry) than most other cohorts that include 
individuals of African descent.  However, there were many lifestyle and cultural differences in 
addition to race between the US and Afro-Caribbean men.  Therefore, we were unable to 
determine if these differential associations are primarily a result of genetic or environmental 
factors.  To better understand the genetic component involved in these disparate associations a 
new study using genetic admixture as a variable is needed.  We propose to conduct a cross-
sectional study examining the association of 25(OH)D with indices of bone strength among older 
African American men from a single community (more homogenous cultural background).  
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After analyzing the DNA, men with ≥50% African admixture will be in one group and the others 
will be in a separate group.  We hypothesize that the correlation between 25(OH)D and indices 
of bone strength will be more likely to be null or negative in men with ≥50% African admixture, 
compared to the other subjects. 
In addition to men of African descent, Hispanics, and Asian men have been understudied 
in this area.  A previous study that included Hispanics in the US found a positive association 
between 25(OH)D and BMD in younger and older adults.(18)  However, Hispanics in the US, 
like African American men, are likely to be 25(OH)D deficient. A methodological issue in 
studying Hispanics is their extremely diverse genetic pool which includes African, Caucasian, 
Asian, and indigenous heredity.  Future research could potentially expand this study design to 
only include Hispanic men (excluding Afro-Caribbean, and individuals with known European or 
Asian ancestry) from a specific Caribbean nation, perhaps Dominican Republic.  We hypothesize 
that 25(OH)D values will be higher among Caribbean Hispanics versus US Hispanics, due to 
greater exposure to UV light.  This association is not well understood among Asian men and 
there are no US studies to our knowledge.  A study in China reported a null finding for 25(OH)D 
and hip aBMD  among 407 men aged 50 or older.(20)  Future research could expand this design 
to include Asian American men.  We hypothesize that 25(OH)D will be positively associated 
with vBMD and other indices of bone strength in Caribbean Hispanics and Asian American men. 
 Adiponectin not leptin was associated with bone loss and incident fractures. Among 
women, but not men, adiponectin was associated with lower rates of bone loss.  Gender modified 
the association between adiponectin and fracture.  In men, the risk of a fracture was 2.1 (p 
trend=0.002) times more likely if they were in the highest adiponectin tertile versus the lowest 
independent of potential covariates including, but not limited to age, race, BMI, and weight loss. 
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In women this association was not statistically significant. The association of leptin with bone 
loss and fractures was largely attenuated by BMI and weight loss in both groups.  
The underlying mechanism that contributes to bone loss and incident fractures among 
individuals with high serum adiponectin needs further investigation.  Based on an in vivo study, 
adiponectin may have a negative impact on bone by stimulating the RANKL pathway and 
inhibiting the production of the decoy receptor for RANKL, OPG.(21)   Studies that examine the 
impact of adiponectin on bone resorption markers are needed.  A recent cross-sectional study in 
China evaluated the association of adiponectin with markers of bone resorption in women.(22)  
They found a positive correlation (among postmenopausal women) between adiponectin and N-
terminal type I collagen telopeptide (NTX) after adjusting for age and fat mass.  We propose a 
study design which evaluates the cross-sectional and longitudinal association of adiponectin and 
markers of bone resorption including NTX and carboxyterminal cross-linking telopeptide of 
bone collagen (CTX) in older adults. We hypothesize that adiponectin will be positively 
correlated with bone resorption markers at baseline.  Also, we conjecture that higher serum 
adiponectin at baseline will be associated with a greater increase in NTX and CTX overtime.   
Prior studies have only reported an association of adiponectin and fractures in men.  In 
our study it was lower BMI, and greater weight loss, that increased the fracture risk in women. 
 To better understand why this association is only significant in men we need to measure the sex   
hormone level in older women and men.  Specifically, we need to assess the correlation between 
adiponectin and bioavailable estradiol and testosterone in women and men.  Past literature shows 
that bioavailable estradiol and testosterone are negatively correlated with adiponectin.(23) We 
hypothesize that the correlation of adiponectin with bioavailable estradiol will be stronger and 
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more likely to explain fracture in women than men.  We also conjecture that the association 
between bioavailable testosterone and adiponectin will be similar in women and men and less 
correlated when compared to estradiol in both populations. Based on these observations we 
would be able to better understand how adiponectin in men not women, acts independently of 
BMI, lean mass, fat and other potential confounders (related to sex hormones) to predict fracture.
This information will ultimately help us to better comprehend the natural history and 
etiology of osteoporosis and osteoporotic fractures as well as the underlying factors for gender 
and racial differences in skeletal health.   
6.3 PUBLIC HEALTH SIGNIFICANCE 
Osteoporosis is a growing major public health problem that leads to disability and an increased 
risk of mortality after a fracture.  Much less is known about determinates of osteoporosis and 
fracture in men compared to women and in minority groups. An estimated 13% of men over the 
age of 50, will have an osteoporotic related fracture, and lose an estimated 1% of their BMD 
every year.(1)  In addition to this public health burden, annual mortality rate after a hip fracture 
is higher in men compared to women.(2)  As life expectancy increases the prevalence of 
osteoporosis and its associated fractures is expected to increase in the general population and 
among various demographic groups.  Also, medical costs for osteoporosis and osteoporotic 
fractures are projected to increase over the next few decades, especially in men.(3)    
            Few studies have comprehensively assessed the risk factors associated with cortical and 
trabecular bone compartments. The study in the MrOS cohort of older men is the largest most 
117 
 
comprehensive study on correlates of vBMD.  Past studies used DXA to estimate BMD however 
this procedure is dependent on bone size (e.g., bone size differs in men compared to women), 
and therefore provides an assessment of areal BMD not volume and does not estimate true 
density. DXA also fails to distinguish trabecular and cortical bone. Bones differ in their 
composition of trabecular and cortical bone.  For example, the spine contains an estimated 65% 
trabecular bone and the femoral neck consists of approximately 75% cortical bone.  Identifying 
correlates of trabecular bone can lead to a better understanding of what factors might be 
associated with spine fracture. On the hand understanding correlates of cortical bone may 
improve our knowledge of the etiology of femoral neck hip fracture.  Also, identifying these 
correlates may facilitate osteoporosis prevention strategies  
Vitamin D deficiency can have a profound impact on bone growth and bone 
mineralization in young adults and on bone loss in older adults.  In addition, our study uses a 
 population of men of African descent with relatively low European admixture (4 grandparents 
of African ancestry required) relative to other black cohorts. This more homogenous population 
allows us to understand these associations better in a population of black men with little 
 or no European admixture.  The association of 25(OH)D and bone is not well understood in men 
of African descent. Blacks have lower fracture rates, greater BMD, but lower 25(OH)D than  
Caucasians.  This paradox is also not understood.  This study attempted to identify hypotheses 
for these disparate associations and to also better comprehend what serum 25(OH)D threshold 
is required to maintain adequate bone strength among to two distinct racial cohorts by using tests 
of threshold.        
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